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Zusammenfassung 
Weltweit wird ein Prävalenzanstieg Typ I allergischer Erkrankungen beobachtet. Vor dem 
Hintergrund einer genetischen Prädisposition tragen verschiedene endogene und exogene 
Einflüsse zur Pathogenese dieser Immunglobulin E (IgE)-vermittelten Krankheiten bei. West-
liche Lebensstilelemente, insbesondere die Ernährungsgewohnheiten, gelten als Risikofakto-
ren für die Ausprägung allergischer Erkrankungen. Die westliche Ernährung ist durch eine 
Zunahme von omega-6 (n-6) mehrfach ungesättigter Fettsäuren (polyunsaturated fatty acids, 
PUFA) sowie eine Abnahme von n-3 PUFA gekennzeichnet. Fischöl, welches reich an n-3 
PUFA ist, ist für seine antiinflammatorischen Effekte bekannt. Ebenso wurde die n-3 PUFA 
Docosahexaensäure (DHA) bei verschiedenen chronisch-entzündlichen Erkrankungen er-
folgreich therapeutisch eingesetzt. Allerdings sind die zugrunde liegenden Wirkungsmecha-
nismen nicht vollständig aufgeklärt. 
Im ersten Teil der Arbeit wurde der molekulare Mechanismus der DHA-vermittelten Hem-
mung der IgE-Produktion in humanen B-Zellen untersucht. Neben einer dosisabhängigen 
Reduktion der anti-CD40/ Interleukin (IL)-4-induzierten IgE-Produktion führte die Behandlung 
von B-Zellen mit DHA zu einer verminderten Differenzierung IgE-produzierender Plasmazel-
len. Dieser DHA-vermittelte Effekt steht in kausalem Zusammenhang zu einer direkten 
Hemmung des Klassenwechselprozesses zu IgE auf dem Niveau des epsilon-
Keimbahntranskriptes (εGLT) sowie der Aktivierungsinduzierten (Cytidin)-Desaminase (AID). 
Weitere Analysen der beteiligten Signaltransduktionswege ergaben, dass DHA sowohl die 
IL-4-abhängige Phosphorylierung des Signaltransduktors und -aktivators der Transkription 6 
(STAT6) als auch die CD40-vermittelte Translokation des nukleären Transkriptionsfaktors 
kappa B (NFκB) p50 in den Zellkern hemmt.  
Um zu überprüfen, ob die ex vivo gewonnenen Erkenntnisse auch in vivo relevant sind, wur-
de in einer randomisierten, kontrollierten Doppelblindstudie die Wirksamkeit einer Supple-
mentierung mit hochdosierter DHA bei Patienten mit atopischem Ekzem hinsichtlich klini-
scher und auch immunologischer Parameter untersucht. In dieser Untersuchung führte DHA, 
aber nicht das Kontrollsupplement zu einer signifikanten Reduktion des Schweregrades der 
Erkrankung. Ferner wurde eine signifikant verminderte IgE-Produktion anti-CD40/IL-4-
stimulierter Blutzellen von DHA supplementierten Patienten festgestellt. Wohingegen die Se-
rum-IgE-Spiegel nicht beeinflusst waren. Parallel wiesen DHA-supplementierte Patienten 
eine erhöhte Konzentration an n-3 PUFA sowie ein reduziertes n-6/n-3-PUFA-Verhältnis im 
Plasma auf. Diese Beobachtungen unterstützen die Resultate des oben genannten 
zellbiologischen Teils und verdeutlichen die klinische Relevanz dieser Daten.  
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Im dritten Teil der Arbeit wurden die lokalen Prozesse in der Haut nach DHA-
Supplementierung untersucht. Hierzu wurde ein Mausmodell eingesetzt, da es aus ethischen 
Gründen nur begrenzt möglich ist, Hautproben von Patienten zu analysieren. In Überein-
stimmung mit den Ergebnissen der klinischen Untersuchung führte die orale DHA-
Supplementierung auch zu einem verbesserten klinischen Bild der proteininduzierten Derma-
titis. Die Reduktion der Symptomstärke und der damit einhergehende verminderte klinische 
Schweregrad des Ekzems waren mit der verringerten Zahl dermaler CD8+ T-Zellen verbun-
den, indessen waren andere Parameter wie Mastzell- und CD4+ T-Zellzahlen sowie 
Epidermisdicke nicht beeinflusst. Da auch im Mausmodell die Serum-IgE-Konzentration nicht 
durch die orale DHA-Verabreichung beeinflusst wurde, wirkt DHA hier vermutlich primär lokal 
als systemisch immunmodulierend. 
Durch die Fähigkeit von DHA in den IgE-Klassenwechsel in B-Zellen einzugreifen, stellt die 
orale Supplementierung mit DHA eine mögliche präventive Maßnahme gegenüber Typ I al-
lergischen Erkrankungen dar. Weiterhin verdeutlichen diese Daten, dass DHA den Schwere-
grad des atopischen Ekzems durch eine positive Beeinflussung lokaler inflammatorischer 
Prozesse signifikant verbessern kann. Um diätetische DHA bestmöglich als therapeutisches 
Instrument im Zusammenhang mit allergischen Erkrankungen einsetzen zu können, muss 
allerdings die Supplementierung hinsichtlich des Zeitpunktes sowie der Dosierung optimiert 
werden. 
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Abstract 
The prevalence of type I allergic diseases have increased worldwide. Based on genetic sus-
ceptibility diverse endogenous and exogenous factors contribute to the pathogenesis of 
these immunoglobulin (Ig) E mediated disorders. The modern life style is hypothesised to be 
one risk factor for allergic diseases. Thereby the Westernised diet is characterised by an in-
creasing consumption of omega-6 (n-6) polyunsaturated fatty acids (PUFA) and a decreasing 
intake of n-3 PUFA. Fish oil, rich in n-3 PUFA, exerts a wide range of antiinflammatory ef-
fects. Docosahexaenoic acid (DHA) is one major n-3 PUFA of fish oil and has been reported 
to be beneficial in different chronic and inflammatory diseases as well. However, the underly-
ing mechanisms of its action are not completely understood.  
The molecular mechanisms of DHA on IgE production in human B cells were examined in the 
first part of this thesis. DHA inhibited IgE production and the differentiation of IgE secreting 
cells in a dose-dependent manner. This inhibition was mediated through direct inhibition of 
the immunoglobulin isotype switching process, which was detected by decreased epsilon 
germline transcript (εGLT) and activation induced (cytidin) desaminase (AID) transcription. 
Analysis of involved signalling pathways revealed that DHA caused both an inhibition of inter-
leukin (IL)-4 driven signal transducer and activator of transcription 6 (STAT6) phosphorylation 
but also a reduced nuclear factor kappa B (NFκB) p50 translocation into the nucleus upon 
anti-CD40 stimulation. 
Next it was verified whether the ex vivo findings are relevant in vivo as well. In a randomised, 
double bind, controlled clinical study the efficacy of high-dose DHA supplementation in atopic 
eczema was determined and thereby the impact on clinical as well as immunological pa-
rameters investigated. In the DHA treated, but not in control group a significant clinical im-
provement of atopic eczema in terms of severity was observed. Additionally, in DHA group a 
significant reduction of anti-CD40/IL-4 mediated IgE synthesis of peripheral blood cells was 
detected whereas serum IgE concentrations remained unchanged. Furthermore, the DHA 
group showed an increase of plasma n-3 PUFA and a decrease of n-6/n-3 PUFA ratio. These 
observations support the findings from the first part of this work and point to their potential 
biological relevance.  
The third part of this work deals with the clinical impact of oral DHA administration on aller-
gen induced dermatitis. Due to ethical considerations analysis of skin biopsies from patients 
is limited. Therefore a mouse model was used. The obtained data correspond to the other 
results. Analysis of the local mechanisms of clinical improvement implicated a favourable 
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modulation of the cellular immune response by DHA. The reduced clinical skin score was 
associated with a decreased number of dermal CD8+ T cells, whereas other parameters like 
epidermis thickening, CD4+ and mast cell numbers were not affected. However, the serum 
IgE values remained unchanged indicating that DHA might rather act locally than systemi-
cally on an established allergic response.  
Taken together the results of this thesis indicate that dietary DHA may be effective in preven-
tion of type Ι allergic diseases by interference with the IgE switching process. Additionally, 
DHA has been shown to improve the clinical outcome of atopic eczema by having a positive 
impact on local inflammatory processes. Dietary DHA might be a potential therapeutical tool 
for dietary management of IgE mediated diseases, like atopic eczema. However, further re-
search in order to reveal the best time-point and optimal dose of DHA application is still nec-
essary. 
Schlagwörter:  
Docosahexaensäure, Mehrfach ungesättigte Fettsäuren, Allergie, IgE 
Keywords:  
Docosahexaenoic acid, Polyunsaturated fatty acids, Allergy, IgE 
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1 Introduction 
1.1 Type I allergic reactions 
Whereas the Western world was experiencing a dramatic increase in the prevalence of aller-
gic diseases during the last 30 to 40 years of the previous century, a similar tendency can be 
currently seen in fast developing countries such as India and China. Even in Arctic region the 
same trend is detected with a doubling of sensitisation rates in only 11 years [1].  
Allergies are inappropriate or exaggerated reactions of the immune system to substances 
that are usually harmless. Allergy inducing substances are called allergens. Common indica-
tions of allergy may include sneezing, itching and skin rashes [2].  
Immediate allergic reactions are manifested as anaphylaxis, rhinoconjunctivitis allergica and 
allergic asthma [3]. These immunoglobulin (Ig) E mediated processes are initiated by the first 
contact between immune system and allergen, the sensitisation phase. Thereby, the allergen 
is internalised and processed by antigen presenting cells (APC; like macrophages, dendritic 
cells [DC], Langerhans cells [LC], B cells). Peptides derived from allergens are presented via 
major histocompatibility complex II (MHC II) to naïve CD4+ cells (TH0) leading to T cell acti-
vation and differentiation into TH2 cells. Signalling molecules of TH2 cells, like CD40 ligand 
(CD40L, CD154) and interleukin (IL)-4, activate B cells to proliferate and differentiate to IgE 
secreting plasma cells [4,5]. The subsequently secreted allergen specific IgE binds to its high 
affinity receptor (FcεRI) on granule containing cells, like mast cells (MC) and basophils. Re-
peated exposure leads to cross linking of receptor bound IgE by polyvalent allergens, what 
triggers the degranulation of MC and basophils. The release of mediators, like histamine and 
prostaglandins (PG), elicits the symptoms of the immediate allergic reaction characterised by 
increased vascular permeability and smooth muscle contraction. The late phase is caused by 
leukotrienes (LT), chemokines and cytokines. The second phase of smooth muscle contrac-
tion and tissue remodelling takes place. Chemokines and local cytokine pattern recruit 
macrophages and neutrophils, but also eosinophils and TH2 cells to sites of inflammation. 
Eosinophilic inflammation is supported by TH2 cell derived IL-5. A sustained allergen expo-
sure with a persisting immune reaction can lead to a chronic inflammation, hallmarked by 
hyperreactivity and damage of the affected tissue [6]. 
1.1.1 Mechanisms and molecular regulation of IgE production 
IgE is the major player of type I hypersensitivities. The heavy chain constant (CH) region do-
mains of IgE are encoded by a single gene, the strictly regulated Cε gene [7]. In serum of 
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non-atopic individuals, IgE is found in very low concentrations ranging between 
1 and 400 ng/mL [7]. This is mainly adjusted by a tight regulation of gene expression and 
protein stability [7]. The rapid turnover and the short half-life of 2.5 days contribute to the low 
serum IgE levels [1]. It has been considered that a high level of serum IgE comes along with 
high IgE production. However, increasing IgE levels lead to diminished IgE catabolism. Thus, 
half-life arises threefold when IgE levels proceed from 0.07 to 35 µg/mL [8]. Furthermore, 
when bound to its high affinity receptor on MC, half-life of IgE is increased up to 8 to 14 days 
[8]. Interestingly, in healthy individuals about 67 % of IgE is found extravascularly compared 
to 48 % in patients with severe atopic diseases [8]. 
According to their CH regions immunoglobulins can be categorised into nine isotypes: IgA1, 
IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4 and IgM. Except IgM and IgD, all other isotypes result 
from class switch recombination (CSR). Thereby, the specificity defining variable region is 
molecularly linked with the constant (C) regions of different isotypes and distinct effector 
functions [6]. 
Switching to all isotypes is commonly regulated at the germline transcription of CH genes and 
the induction of activation induced (cytidine) desaminase (AID) expression. Switching from 
naïve B cell expressing IgM and IgD to IgE can occur directly or sequentially via IgG. This 
process is induced by two signals: antigen specific T cell interaction with B cell via 
CD40L/CD40 and IL-4 secreted by activated T cells [5].  
IL-4 and IL-13 exert their biological effects by binding to the IL-4 receptor (IL-4R) complex, 
which consists of two subunits (Figure 1). Type I IL-4R complexes, composed of IL-4Rα 
chain and γc chain, bind IL-4 but not IL-13. IL-4 and IL-13 can bind to Type II IL-4R com-
plexes, which are composed of IL-4Rα and IL-13Rα1. Both receptor complexes amplify their 
signals through IL-4Rα. A second IL-13 receptor, IL-13Rα2, binds to IL-13 exclusively and 
serves as a decoy receptor. IL-4 binding mediates receptor heterodimerisation and activation 
of cytoplasmic protein tyrosine kinases called Janus activated kinases (JAK) which are con-
stitutively associated with IL-4Rα (JAK1) and γc chain (JAK3) [9,10]. 
Tyrosine phosphorylation of the IL-4Rα (Y575, Y603, Y633) enables the recruitment of signal 
transducer and activator of transcription 6 (STAT6) through the SH2 domain. Further STAT6 
phosphorylation by JAK and dimerisation result in translocation to the nucleus, where it acti-
vates the transcription of IL-4 and IL-13 responsive genes. STAT6 dephosphorylation stimu-
lates its export into cytosol, where it can be recruited into another cycle of tyrosine phos-
phorylation and nuclear entry [10]. 
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Figure 1: Illustration of IL-4R and IL-13R complexes focussed on IL-4Rα signalling 
[9,10]. Type I IL-4R complexes are composed of IL-4Rα and γc and bind exclusively to IL-4. 
Type ΙΙ IL-4R complexes consist of IL-4Rα and IL-13Rα1 and bind to both IL-4 and IL-13. 
Signalling via IL-13Rα1 include additional intermediates like STAT3. The second IL-13 recep-
tor IL-13Rα2 exclusively binds to IL-13. Signalling pathways activated via IL-4Rα are de-
picted in more detail. Receptor binding of IL-4 and IL-13 promotes activation of members of 
the JAK family that constitutively associate with component subunits of the receptor com-
plexes. Thereby, several intracellular signalling cascades are initiated by phosphorylating 
specific tyrosine residues in the cytoplasmic domain of IL-4Rα. These phosphorylated resi-
dues act as connecting sites for signalling molecules. The first residue represents the insulin/ 
interleukin-4 receptor (I4R) motif which facilitates the interaction with Shc and insulin receptor 
substrate (IRS) proteins. Phosphorylated IRS binds to phosphatidylinositol 3-kinase (PI3-K) 
which controls several protein kinases regulating proliferation. Together with PI3-K connected 
pathways, Shc mediates the regulatory functions of I4R motif and activates components of 
mitogen-activated protein kinase (MAPK) cascade. Phosphorylation of tyrosine residue cas-
sette recruits transcription factor STAT6. JAK phosphorylate STAT6 which lead to its dimeri-
sation and translocation to the nucleus, where it activates the transcription of IL-4 and IL-13 
responsive genes like AID. The last tyrosine residue binds to the phosphatase Src homology 
domain 2 (SH2) containing inositol phosphatase (Shp-1), which is a negative regulator of 
receptor signalling. Thus, the multiple effector functions of IL-4Rα are transmitted by the 
STAT6 and the I4R pathways separately and in combination.  
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In addition to the JAK-STAT pathway, IL-4 also induces tyrosine phosphorylation of IRS-1 
and/or IRS-2, which mediate the activation of PI3-K. Thereby I4R motif, a conserved tyrosine 
residue of IL-4Rα (Y497, Y500), engages phosphotyrosine binding domain adaptor proteins, 
like IRS and Shc, which may be also involved in IgE regulation [9,11]. 
IL-4Rα also bears an immuno-tyrosine inhibitory motif (ITIM) site at Y713 and its adjoining 
residues, which binds to several regulatory phosphatases, including Shp-1. It is discussed as 
a negative regulator in IL-4Rα signalling in STAT6 activation [9].  
CD40 is a member of the tumor necrosis factor receptors (TNFR) family (Figure 2). Since its 
cytoplasmic tail does not have an intrinsic kinase activity, downstream signalling is transmit-
ted by the adapter molecules TNFR associated factors (TRAF) [12]. CD40 ligation results in 
rapid recruitment of TRAF1, TRAF2, TRAF3 and TRAF6 to the CD40 cytoplasmic domain 
[13]. TRAF2 and TRAF3 are drafted to the cell membrane after CD40 engagement, which 
allows the contact to membrane cholesterol-rich microdomains or lipid rafts. Subsequently 
TRAF2 induces its own as well as TRAF3 ubiquitylation. Degradation of these TRAF occurs 
in cytoplasmic proteasome [13].  
TRAF1 is implicated in regulation of other TRAF and enhances the TRAF2 degradation. 
TRAF2 and TRAF6 are essential for c-jun kinase (JNK) and p38 activation, but also nuclear 
factor kappa B (NFκB) signal. TRAF3 negatively regulates JNK and NFκB activation by com-
petitive binding of TRAF2 to CD40. Additionally, TRAF3 inhibits the interaction between B cell 
receptor and CD40 [13]. Besides TRAF numerous kinases, like germinal centre kinase 
(GCK) contribute to CD40 signal transduction [14]. The transcription factors activator pro-
tein 1 (AP1) is also induced and its signalling pathway involves JNK and p38 [13].  
The activation of NFκB by TRAF2 and TRAF6 starts with NFκB inducing kinase (NIK). This 
MAPK phosphorylates and thus activates the inhibitor of NFκB (IκB) kinase complex (IKKα, 
IKKβ and IKKγ) which leads to phosphorylation of IκB proteins. Following IκB degradation, 
liberated NFκB translocates to the nucleus where it regulates the expression of a wide spec-
trum of genes [13,14,15].  
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 Figure 2: CD40–TRAF activated signalling cascades lead to gene regulation [13,16]. 
In B cells CD40 ligation activates NFκB pathway via TRAF2 and TRAF6. Thereby NFκB sig-
nalling is initiated through activity of NIK leading to activation of the IKK complex. IKK phos-
phorylates the inhibitory IκB thereby promoting their ubiquitylation and proteasomal degrada-
tion. Consequently, liberated p50/p65 heterodimers (NFκB type 1) translocate into nucleus 
regulating a wide spectrum of genes. Furthermore, IKK complex induces the formation of p52 
through phosphorylation induced, ubiquitin dependent processing of p100. The subsequently 
activated p52/Rel-B heterodimers (NFκB type 2) target distinct elements. In B cells CD40 
ligation mainly activates NFκB by the rapid NFκB type 1 pathway; beside this the more sus-
tained NFκB type 2 cascade. TRAF6 additionally induces activation of the transcription factor 
AP1, whereas TRAF2 activates MEKK1 (MAPK/extracellular signal-regulated kinase [ERK] 
kinase kinase 1) and JNK. 
Each immunoglobulin region is composed of a short germline exon (Ι), a repetitive GC-rich 
switch region (S) and several exons encoding the CH region (Figure 3). In case of IgE switch-
ing, STAT6 and NFκB bind to epsilon germline gene promoter initiating sterile germline 
mRNA transcript (εGLT), which is not translated into a functional protein and lacks VDJ re-
gion. Both transcription factors synergise for IgE transcription and maximal IgE production 
[1,7].  
STAT6 and NFκB also bind to a site in the upstream region of the AID gene and thereby con-
tribute to an increase in available AID enzyme during the DNA rearrangement process [7]. 
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Figure 3: εGLT and AID transcription is induced by IL-4 and CD40 ligation [5]. Liga-
tion of the IL-4R by IL-4 recruits and activates the tyrosine kinases JAK1 and JAK3, thereby 
activating STAT6. CD40 stimulation by CD40L on T cells permits the activation of TRAF lead-
ing to nuclear translocation of NFκB and AP1. IL-4R and CD40 signalling promote the syner-
gistic enhancement of transcription of both the εGLT (Cε GLT) and AID by NFκB and STAT6. 
Transcription at the CH locus, which is induced by specific cytokine signals, precedes CSR. 
εGLT originate at a promoter upstream of the Ι exon and do not encode functional proteins. 
C/EBP, CCAAT/enhancer binding protein; PAX5, paired box protein 5. Reprinted by permis-
sion from Macmillan Publishers Ltd: Nature Reviews Immunology (2003 Sep;3(9):721-32), 
copyright (2003); http://www.nature.com/nri/index.html.  
The εGLT transcription is initiated at the Iε exon, transcribed through the S and CH genes and 
completed at the usual termination sites for mature mRNAs (Figure 4). Association of εGLT 
with the genomic S region lead to formation of RNA-DNA hybrids (R-loops). The R-loop 
structure results in a single stranded DNA segment, which is targeted by AID. This enzyme 
desaminats dC to dU within S regions, thereby generating an U:G mismatch which is proc-
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essed through uracil removal, base-excision or mismatch repair. In order to achieve CSR by 
an intrachromosomal deletion, double strand DNA breaks are brought into both the upstream 
Sµ/γ and the downstream Sε region [1,7,17]. Since there is an almost linear correlation be-
tween S region size and CSR frequency, the low IgE expression levels are supported by the 
small size of the Sε region [7]. 
 
Figure 4: Deletional CSR of the human immunoglobulin locus [5]. During B cell de-
velopment immunoglobulin heavy chain loci are rearranged and contain clusters of heavy 
chain variable (V), diversity (D) and joining (J) cassettes. This process results in a complete 
rearranged VDJ region encoding an antigen binding domain capable of generating intact µ 
and δ heavy chains. The production of other antibody isotypes that have the same antigen 
specificity requires an additional excision and repair process - known as deletional CSR. Dur-
ing CSR a defining variable region is molecularly linked with constant regions of different 
isotypes and distinct effector functions. This involves the excision of a piece of genomic DNA 
spanning from Sµ sequences to the targeted downstream S sequence. Association of the 
VDJ sequences to the Cε locus gives rise to an integral ε heavy chain gene and the produc-
tion of intact IgE antibodies. Membrane IgE RNA is encoded by splice isoforms with the M1 
and M2 exons. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Im-
munology 2003 Sep;3(9):721-32), copyright (2003); http://www.nature.com/nri/index.html. 
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1.2 Atopic eczema  
Atopic eczema is a chronically relapsing, inflammatory skin disease associated with ery-
thema, severe pruritus, crusty and oozing plaques on forehead, face, neck and hands [18]. 
The pathogenesis is driven by a complex combination of environmental, genetic, immu-
nologic factors and skin barrier dysfunctions [19,20].  
The incidence of atopic eczema is increasing worldwide and varies in different populations. 
10 to 20 % of infants and children and 1 to 3 % of adults are affected by this disease, 
whereas the prevalence of atopic eczema varies between 2 and 5 % in the whole population. 
In most cases, about 70 %, manifestation occurs within the first five years of life. At later age 
30 to 60 % of children suffering from this disease develop respiratory diseases such as 
asthma or hay fever (atopic march) [20,21]. Thus, atopic eczema causes high costs and is a 
serious socioeconomic burden besides its negative impact on the quality of life of suffering 
patients [18,20,22,23]. 
Two types of atopic eczema have been delineated. Most patients (70 to 80 %) suffer from the 
extrinsic type of atopic eczema which is associated with an IgE mediated sensitisation. By 
contrast, the intrinsic type does not seem to be linked to IgE related mechanisms and affects 
20 to 30 % of atopic eczema patients. Cutaneous lymphocyte associated antigen (CLA) ex-
pressing memory T cells are recruited to the skin where they produce higher amounts of TH2 
cytokines. IL-4 and IL-13 induce the isotype switching towards IgE, whereas IL-5 leads to 
eosinophil expansion and survival. Inheritance and other internal processes are associated 
here. Intrinsic atopic eczema is characterised by a lower IL-4 and IL-13 production compared 
to extrinsic form. However, few patients suffer from both extrinsic and intrinsic form [20,22]. 
1.2.1 Pathophysiology of atopic eczema 
The pathophysiology of atopic eczema involves genetic predisposition, disturbed skin barrier 
function, defects in the antimicrobial immune defence and frequent allergic responses 
against allergens [19,20]. 
A high familial association has been described for atopic eczema. Genetic research was fo-
cussed on specific atopic eczema alleles, as well as identifying overlapping genes associ-
ated with other allergic disorders. Genetic polymorphisms have been assigned for a cluster 
of TH2 cytokine genes located on chromosome 5q22-23, the IL-13 coding region and the 
IL-4Rα subunit (16q12) [20,21,24]. Heritable epidermal barrier defect has been shown to be 
connected to the filaggrin (filament-aggregating protein) gene (FLG). FLG mutations are a 
major risk factor for eczema associated asthma [21,24].  
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Atopic eczema is characterised by dry skin with increased transepidermal water loss. The 
disturbed barrier function results from a reduced activity of acid ceramidase and decreased 
ceramides content, the most important water retaining molecules in the extracellular space. 
Additionally, this dysfunction causes a reduction of sphingosine levels in the stratum 
corneum. Since sphingosines are potent antimicrobials, the colonisation with Staphylococcus 
aureus (S. aureus) is supported. Diminished levels of additional antimicrobial peptides, e.g. 
β-defensine 2 and cathelicidin, promote the ongoing colonisation of inflamed skin by various 
microorganisms [20,21].  
The TH2 predominance in atopic eczema patients, resulting from an increased frequency of 
allergen specific TH2 cells and a decrease of interferon (IFN) γ producing cells, favours IgE 
production and peripheral eosinophilia. Disturbed cellular immunity, humoral factors like in-
creased IgE synthesis and high production of related cytokines contribute to development of 
skin lesions [18,20].  
Clinically unaffected skin in atopic eczema is characterised by sparse perivascular T cell infil-
trate, increased number of TH2 cells expressing IL-4 and IL-13, but not IFNγ [25] (Figure 5).  
Initially, allergens penetrate into damaged skin and activate DC by cross linking FcεRI bound 
IgE molecules leading to an enhanced antigen presentation capacity. In this phase naive 
T cells are polarised into TH2 cells producing associated cytokines. Additionally, MC are acti-
vated via antigen specific IgE and contribute to induction of the inflammatory response [22].  
Very early events initiating atopic skin inflammation are not completely elucidated. Environ-
mental allergens, scratching or microbial toxins cause skin injury thereby activating keratino-
cytes, MC and DC to release proinflammatory cytokines and chemokines, like IL-1, thymic 
stromal lymphopoietin (TSLP) and TNFα. Local proinflammatory mediator expression or-
chestrates adhesion to the endothelium and subsequent extravasation of cells and thus de-
fining the nature of the inflammatory infiltrate. These mediators enhance the expression of 
adhesion molecules on vascular endothelium and facilitate the extravasation of inflammatory 
cells into the skin. In the tissue these cells respond to chemotactic gradients established by 
cytokines and chemokines originated from sites of injury or infection [20,26]. Cutaneous T 
cell attracting chemokine (CCL27) is pivotal in mediating the migration of CLA+ T cells. Addi-
tionally, macrophage derived chemokine and activation regulated cytokine are increased in 
patients with atopic eczema. These molecules selectively recruit CCR4 expressing TH2 cells. 
Dimension of thymus and activation regulated cytokine levels have been linked to severity of 
atopic eczema [20].  
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Figure 5: Immunological processes in the skin involved in the pathogenesis of 
atopic eczema [20]. Circulating CLA expressing TH2 cells lead to elevated serum IgE and 
eosinophil numbers. These T cells recirculate through unaffected skin where they can en-
gage allergen triggered IgE+ LC and MC supporting TH2 cell pattern. Skin injury provokes 
keratinocytes to release proinflammatory cytokines and chemokines thereby enhancing the 
expression of adhesion molecules on vascular endothelium and facilitating extravasation of 
inflammatory cells into skin. Keratinocyte derived TSLP and MC originated IL-4 enhance TH2 
cell differentiation. In acute skin lesions, TH2 cell numbers are increased, but chronic eczema 
results in the infiltration of inflammatory dendritic epidermal cells (IDEC), macrophages (MΦ) 
and eosinophils. IL-12 production provokes the switch to a TH1 cytokine milieu associated 
with increased IFNγ expression. Ag, antigen; SAg, superantigen; AICD, activation induced 
cell death. Reprinted from Akdis CA et al.: Diagnosis and treatment of atopic dermatitis in 
children and adults: European Academy of Allergology and Clinical Immunology/American 
Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report, J Allergy Clin 
Immunol 2006;118(1): 152-69, Copyright (2006), with permission from Elsevier. 
Acute eczematous skin lesions are clinically designated by extremely pruritic, erythematous 
papules associated with excoriation and serious exudation. Memory CD4+ cells infiltrate into 
the dermis. Compared to unaffected skin, acute skin lesions show a significantly larger num-
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ber of TH2 cells, but only few TH1 cells. Importantly, LC, IDEC and macrophages in lesional 
and, to a lesser extent, in non-lesional skin bear IgE [20,25]. 
Due to ongoing inflammation, chronic lichenified skin lesions have undergone tissue remod-
elling. The clinical criteria are thickened plaques with increased markings (lichenification) and 
dry, fibrotic papules. Collagen deposition during chronic atopic eczema results from in-
creased expression of the profibrotic cytokine, IL-11. While T cells remain present, although 
in smaller numbers than seen in acute atopic eczema, macrophages dominate the dermal 
mononuclear cell infiltrate. Increased number of IgE bearing LC and IDEC are found in the 
epidermis. Inflammatory response is also supported by eosinophils. The late phase switch to 
TH1 depicts the chronicity of the atopic lesions, characterised by an increased production of 
the related cytokines, such as IFNγ and IL-18 [20,27]. 
1.2.2 Atopic eczema and fatty acids 
Previous studies have shown abnormalities in fatty acid metabolism in atopic eczema. This 
aberration is hallmarked by an elevated concentration of the omega-6 (n-6) polyunsaturated 
fatty acid (PUFA) linoleic acid (LA, 18:2n-6) and reduced levels of LA metabolites in blood, 
milk and adipose tissue. The same phenomenon was observed for n-3 PUFA with an in-
creased α-linolenic acid (ALA, 18:3n-3) concentration and a decrease of its metabolites. In-
terestingly, a positive correlation was found between LA concentration and IgE levels [28], 
but also an inverse association between γ-linoleic acid (GLA, 18:3n-6) or arachidonic acid 
(AA, 20:4n-6) levels and IgE [29]. This suggests a correlation of LA metabolism impairment 
and the risk of developing atopic eczema [28]. 
These aberrations in PUFA proportions reflect the reduced activity of the responsible enzyme 
∆6-desaturase which may result from a enzyme mutation, altered expression, modifications 
in responsible cofactors, alterations in hormonal regulation or the presence of enzyme inhibi-
tors [28]. This enzyme determinates the rate limiting step in desaturase / elongase pathway. 
The generated metabolites serve as precursors for immunomodulators such as PG and LT 
[30]. At birth these fatty acid alterations are already existent and precede the development of 
the skin lesions [28]. If there is a causal dependence, a deficit of certain essential fatty acids 
in infancy could impede normal skin function and lead to abnormal maturation and sensitisa-
tion of the immune system. Due to the memory of the immune system, these immunological 
aberrations and their relevance for the skin might not be resolved by correction of the fatty 
acid abnormalities after sensitisation. However, substitution of suitable fatty acids is expected 
to regulate the element of skin damage directly [28]. 
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On this basis, several studies have been focused on counterbalancing this lack of n-6 PUFA 
with oral substitution of natural plant derived oils rich in GLA, such as primrose oil and bo-
rage oil, but a meta-analysis suggested no significant clinical benefit from n-6 PUFA in atopic 
eczema [30].  
Because of its known antiinflammatory effects, some clinical trials were also focused on n-3 
PUFA. Benefits by n-3 PUFA supplementation were shown for diseases like rheumatoid ar-
thritis and psoriasis [31]. Subsequently n-3 PUFA application in atopic eczema patients was 
considered and examined clinically. However, only Mayser et al. [32] demonstrated a signifi-
cant amelioration of the clinical outcome by daily infusions of n-3 PUFA. This therapeutical 
effect was accompanied by alterations in fatty acid profile of the membrane lipid pool as well 
as alterations in eicosanoid synthesis. Besides Gimenez-Arnau et al. [33] all other trials illus-
trated a non-significant advantage of n-3 PUFA by predominantly oral supplementation 
[34,35,36]. Few trials report additionally subjective patient ratings of disease expression with 
statistically significant results in some subscales in one study [37,38].  
1.2.3 Murine models of atopic eczema 
Animal models are indispensable research tools to study pathogenic mechanisms and to 
evaluate novel treatments. For this purpose an animal model has to meet distinct important 
criteria [39]:  
• Display of the cardinal symptoms of the disease 
• Reproducibility of induction / occurrence of disease phenotype 
• Detailed knowledge of model organism 
• Sufficient evolutionary homology 
• Possible data transfer to man  
Besides humans, mice, dogs, cats and horses have been reported to develop atopic eczema 
like skin lesions. A number of analogies regarding clinical manifestation, immunological as-
pects and histological findings between atopic eczema in humans and in dogs, cats or horses 
were determined. But only mice offer inbred strains displaying a stable disease phenotype.  
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The majority of the above mentioned criteria are fulfilled by most mouse models of atopic 
eczema and offer numerous additional advantages [39]: 
• Small size 
• Low housing costs 
• Short generation time and large number of offspring 
• Detailed knowledge about immune system and skin physiology 
• Genetically modified mice (transgenic, conditional knock out, knock in, etc.) 
• Control of age dependency and of environmental factors  
Various mouse models are employed in the research field of atopic eczema. Genetically en-
gineered mice, mice with spontaneous manifestation of atopic eczema like skin lesions, hap-
ten induced models or humanised models of atopic eczema generated in mice with severe 
combined immunodeficiencies are applied for analysis of pathogenic mechanisms or evalua-
tion of novel therapeutic concepts [39,40,41,42,43]. 
Epicutaneous (e.c.) exposure to allergens is an important trigger factor in pathogenesis of 
atopic eczema [22]. Different protein sensitisation protocols have been used to induce atopic 
eczema like skin lesions in mice, thereby varying the paths of antigen application for sensiti-
sation, using different mouse strains, applying various proteins, allergen extracts or recombi-
nant allergens. Each of these protocols was designed to address particular aspects of atopic 
eczema [39]. Adapted from this, Wang et al. [44] and Spergel et al. [45] established a murine 
model of atopic eczema elicited by repeated e.c. exposures to ovalbumin (OVA). This model 
features significant increased total and antigen specific IgE, significant epidermal thickening, 
cellular infiltration composed of T cells, eosinophils and macrophages as well as a local 
upregulation of IL-4, IL-5 and INFγ mRNA. Thus, several classical hallmarks of human atopic 
eczema are displayed by this model. E. c. sensitisation with protein is a potent inducer of 
systemic TH2 response. [46]. 
However, these models describe important aspects, but up to now no model has integrated 
all aspects of the complex pathophysiology of atopic eczema. One important limitation is the 
difficulty of extrapolation from animal studies to human skin, due to the existing differences in 
immunological as well as in skin (barrier) parameters [47]. 
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1.3 Polyunsaturated fatty acids (PUFA) 
Historically “fat” has been considered important as a high calorific nutrient and a source of 
essential fatty acids. Today, fat and in particular fatty acids have been accepted as important 
biological regulators. Modifications in dietary fatty acids change cell membrane structure and 
function. Furthermore, fatty acids differentially influence the production of cytokines, chemo-
taxis and other immunologic factors. They are known to modulate signal transduction, en-
zyme activities, receptor expression, cell proliferation and differentiation [48]. 
1.3.1 Nomenclature and molecular structure of PUFA 
One criterion for the classification of fatty acids is the number of carbon atoms present in 
hydrophobic hydrocarbon chain (chain length). Thus it is distinguished between short 
chained (< 4), middle chained (6 - 10) and long chained fatty acids (> 10). Besides saturated 
fatty acids, without any double bond and monounsaturated fatty acids, containing a single 
double bond, there are PUFA which comprise at least two double bonds in their hydrocarbon 
chain. In line with the nomenclature, PUFA are designated by their chain length (C), the 
number of double bonds (D) and the position of the first double bond proximal to the terminal 
methyl group (n-). Therefore, the structure of fatty acids is described by the commonly used 
short hand nomenclature as following C:Dn-x. 
According to their fatty acid precursor, four independent PUFA families are classified: The 
omega-3 (n-3) series are derived from ALA (18:3n-3), the n-6 series descended from LA 
(18:2n-6); the n-9 from oleic acid (OA, 18:1n-9) and the n-7 series from palmitoleic acid 
(16:1n-7). It is important to mention that beyond PUFA only LA and ALA are essential, i.e. 
they cannot be synthesised in the human body and thus have to be obtained from the diet 
[49,50,51].  
1.3.2 Dietary Sources of PUFA 
LA is mainly found in cereals, eggs, vegetable oils, like sunflower and corn oils, margarine 
and whole grain breads. The main dietary sources of ALA are vegetable oils like canola oil, 
flaxseed oil, linseed and rapeseed oils, but also walnuts.  
The longer fatty acids of n-3 and n-6 PUFA are either biosynthesised after intake of their pre-
cursors or are obtained directly from animal and marine sources. AA is found in modest 
amounts in human milk and in small amounts in cow’s milk. Egg yolk, meat, but also liver and 
brain contain large amounts of AA. 
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The major dietary source of eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic 
acid (DHA, 22:6n-3) is marine oily fish and some species of algae and other seafood. 
Thereby the content of EPA and DHA varies from species to species according to diet, water 
temperature and season. Fresh water fish is unlikely to contain significant amounts of EPA 
and DHA [52]. 
1.3.3 Physiological function of PUFA 
PUFA and fatty acids in general exert a variety of physiological functions within immune cells. 
They operate as [53]: 
• Energy sources 
• Elements of cell phospholipids contributing to the physical and functional membrane 
characteristics 
• Covalent modulators of protein structure modifying their location and function 
• Regulators of gene expression either through effects on receptor activity, on intracellular 
signalling processes or on activation of transcription factors 
• Precursors for bioactive lipid mediators like PG, LT, lipoxins and resolvins  
1.3.4 Metabolism of PUFA 
In most tissues the metabolism of PUFA includes the alternating sequence of ∆6-
desaturation, elongation and ∆5-desaturation (Figure 6). A new cis-double bond is formed by 
removal of two hydrogen atoms followed by insertion of two carbon atoms from glucose me-
tabolism in order to elongate the fatty acid chain. Thereby ∆6-desaturase catalyses the con-
version of LA (18:2n-6) to GLA (18:3n-6) whereas ∆5-desaturase is responsible for the gen-
eration of AA (20:4n-6) from dihomo-gamma linolenic acid (DGLA, 20:3n-6). The intermediate 
step, the transformation of GLA to DGLA, is catalysed by the elongase. The same set of ∆6-
and ∆5-desaturases and elongases metabolise ALA, LA and OA with the following sequence 
of preference: n-3 > n-6 > n-9 [49,54,55].  
Generated longer PUFA are incorporated into cell membrane. After liberation by phospholi-
pase (PL) they serve as precursors of bioactive lipids like eicosanoids, protectins and re-
solvins [31]. The immune cell phospholipids from typical Western diet consuming individual 
contain about 20 % of fatty acids as AA, 1 % EPA and 2.5 % DHA. An altered consumption of 
certain fatty acids can modify this composition [53]. Thus, increased (long chain) n-3 PUFA 
intake leads to higher proportions of EPA and DHA in cell phospholipids. This incorporation 
occurs dose-dependently and is partly at expense of AA [31,50,54]. 
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Figure 6: Metabolic pathways of n-6 and n-3 long chain PUFA, according to [54,56]. 
Broken arrows represent retroconversion cascades. 
1.3.5 PUFA and immune system 
On the basis of their physiological functions, fatty acids can mediate their biological action at 
different cellular levels [53]: 
• By alterations in the pattern of lipid mediators 
• Through changes in the physical membrane characteristics  
• By modulation of membrane receptor expression, activity or avidity  
• By alteration of intracellular signal transduction  
One key link between PUFA action and function of the immune system is the generation of 
eicosanoids and resolvins from 20-carbon PUFA. Cell membrane phospholipids contain large 
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amounts of AA. This n-6 PUFA is the major precursor for eicosanoids, a family of hydroxy-
lated PUFA with a wide range of functions on inflammatory and immune responses [31,53].  
Cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P 450 pathways competitively 
metabolise AA and EPA to eicosanoids such as PG, thromboxanes (TX), LT, lipoxins and ep-
oxy-compounds. Incorporation of increased amounts of EPA and DHA into cell membranes 
results in a higher formation of EPA derived products at expense of AA derived mediators. 
This is caused by decreased availability of AA as enzyme substrate and inhibition of AA me-
tabolism [53,57]. EPA and DHA are poor COX and LOX substrates compared to AA. Due to a 
mislocalisation of carbon 13, EPA is only inadequately metabolised by COX-1. Therefore, 
EPA competitively inhibits AA metabolism to its eicosanoids. Equally, DHA inhibits AA derived 
mediator synthesis either itself or by retroconversion to EPA [58]. 
After liberation from membrane phospholipids the typically highly abundant AA is metabolised 
through COX to PG and TX of the 2-series, e.g. PGE2 and PGF2a. Metabolism of AA via 
5-LOX provides 5-hydroxyeicosatetraenoic acid and the 4-series of LT, e.g. LTA4 and LTB4 
[58]. These mediators have been shown to exert proinflammatory but also antiinflammatory 
properties [54]. 
Since EPA also operates as a substrate for COX and LOX, an increased availability of EPA 
potentially results in increased production of EPA derived eicosanoids such as PGE3 and 
5-series LT [53]. The functional significance of these mediators originated from EPA is the 
proven lower biological activity compared to those from AA. For example, LTB5 is 10- to 
100-fold less potent neutrophil chemotactic agent than LTB4 and PGE3 [31]. Long chained 
n-3 PUFA are also metabolised to resolvins (from EPA and DHA) and docosanoids (from 
DHA) through pathways involving COX and LOX. These mediators are antiinflammatory, im-
munomodulatory and resolve inflammation [53,54,59]. However, the physiological or patho-
physiological outcome is designated by cells present, the nature of stimulus, timing of eico-
sanoid generation, concentrations of different bioactive lipids as well as sensitivity of target 
cells and tissues to generated mediators [53]. 
N-3 PUFA are mainly found at position sn-2 of membrane phospholipids, thereby replacing 
AA. PUFA incorporation into membrane lipids decreases the membrane microviscosity influ-
encing the mobility, expression and function of membrane proteins [54]. Importantly, 
n-3 PUFA containing phospholipids are also found in lipid rafts, thereby modulating cellular 
signalling processes [49,58]. “Membrane rafts are small (10 to 200 nm), heterogeneous, 
highly dynamic, sterol and sphingolipid enriched domains that compartmentalise cellular 
processes. Small rafts can sometimes be stabilised to form larger platforms through protein–
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protein and protein–lipid interactions” [60]. Proteins are anchored in the membrane rafts 
exoplasmically by glycosyl phosphatidylinositol or cytoplasmically by acyl moieties. Many 
proteins involved in signal transduction are modified in this way and / or concentrated in lipid 
rafts [58]. 
PUFA treatment was shown to modify the cytoplasmic leaflet of lipid rafts, thereby selectively 
displacing acylated proteins and integrating n-3 PUFA. Moreover, dietary n-3 PUFA supple-
mentation reduces significantly the sphingomyelin content of lipid rafts in vivo. This causes 
an altered exoplasmic membrane leaflet and folds acyl chains in the cytoplasmic leaflet. In-
corporation of PUFA as a replacement for saturated fatty acids or changes in raft lipid com-
position could lead to modified protein acylation and thus protein displacement from lipid rafts 
[58]. Additionally, changing the fatty acid composition of immune cells affects phagocytosis, 
T cell signalling and antigen presentation at the membrane level suggesting important roles 
of fatty acids in membrane order, lipid raft structure and function as well as membrane traf-
ficking [53]. 
Cells are responsive to extracellular signals by an up or downregulated expression of specific 
genes which leads to altered metabolism, proliferation, differentiation or apoptosis. Receptor 
mediated signal transduction pathways transmit these extracellular signals to their intracellu-
lar targets. In addition to their roles as structural components of membrane lipids and as pre-
cursors of eicosanoids, fatty acids can act as second messengers or regulators of signal 
transducing molecules [61]. Signalling molecules that may be modulated by different fatty 
acids are divided into three groups: 
1.3.5.1 Signalling molecules that require fatty acid acylation for membrane translocation 
and functional activation 
Translocation and protein function can be dramatically influenced by covalent attachment of 
long chain fatty acids to a wide range of proteins. Many molecules involved in transmitting 
extracellular signals are acylated for their membrane translocation. Cotranslational myristoy-
lation and posttranslational palmitoylation are described in this manner [61]. 
1.3.5.2 Lipid mediators containing different fatty acids or free fatty acids 
PI3-K phosphorylate various phosphoinositides and regulate multiple cell functions such as 
chemotaxis and apoptosis. The activity of the newly generated phosphatidylinositol 
3,4,5-trisphosphate varies with types of fatty acids in the sn-1 and sn-2 positions of phospho-
inositides which can be altered by dietary fatty acids [61]. 
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Hydrolysis of sphingomyelin creates ceramide containing one fatty acyl moiety linked to the 
sphingosine backbone by an amide bond. Ceramide acts as an intracellular signal effector 
molecule with several downstream targets onto various extracellular signals. Thus, control-
ling ceramide activity by dietary fatty acids would exert profound nutritional implications [61]. 
Since the composition of membrane phospholipids is influenced by diverse dietary fatty ac-
ids, fatty acyl residues of diacylglycerol (DAG) may also be altered by dietary fatty acids. It 
has been shown that the capacity to activate the protein kinase C (PKC) is regulated by fatty 
acid esterification at the sn-1 or sn-2 position of DAG [61]. The activation of PKC is enhanced 
via DAG by cis-unsaturated fatty acids like DHA, whereas other PUFA, especially AA in-
creases the activation of PLCγ. Additionally, AA and other PUFA control the activities of multi-
ple cellular proteins, including ion channels and protein kinases [61]. 
1.3.5.3 Signalling molecules that can be modulated by different fatty acids 
Nuclear receptors, a family of ligand activated transcription factors, are able to control sev-
eral genes involved in lipid metabolism and inflammatory signalling directly and indirectly. 
Ligand binding leads to conformational changes which enable the nuclear receptors to disso-
ciate their corepressors and recruit coactivator proteins to allow transcriptional activation 
[54]. Various PUFA and prostanoids are ligands for peroxisome proliferator activated receptor 
(PPAR), a nuclear hormone receptor regulating the transcription of genes involved in lipid 
metabolism but also in diverse cellular responses [61]. Longer chain PUFA, but not shorter 
chain monounsaturated or saturated fatty acids, are able to repress the liver X receptor 
(LXR) enhancer complex in the sterol regulatory element binding protein (SREBP) 1c pro-
moter region [48]. The discussed “cross-talk” between PPAR signalling, retinoic acid X recep-
tor (RXR), SREBP expression and LXR may influence basically cell lipid homeostasis in a 
highly complex but coordinated manner. Due to the various characteristics and the exhibited 
transcriptional regulatory properties of each n-3 PUFA, the subsequent effects of these inter-
actions are also highly complex [48,54].  
Furthermore, it has been shown that n-3 PUFA inhibit NFκB activity directly. EPA diminishes 
degradation of the IκB thereby blocking NFκB. AA derived prostanoids inhibit NFκB translo-
cation and activation by potently blocking the IKK complex and thus retaining NFκB in the 
cytoplasm. Consequently, n-3 PUFA and fatty acid derived mediators modulate manifold the 
NFκB pathway [54]. 
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1.3.6 Docosahexaenoic acid (DHA) 
Due to the structural characteristics of 22 carbons and six double bonds, DHA (22:6n-3, Fig-
ure 7) represents an extreme example of n-3 PUFA family. Primarily dietary studies revealed 
the favourable impact of DHA on diseases like rheumatoid arthritis, asthma, dermatitis and 
psoriasis [62,63]. Thus, the cell membrane is discussed to be one major target of DHA ac-
tion. DHA is readily incorporated into membrane phospholipids and has been demonstrated 
to alter significantly many basic properties of membranes including acyl chain order and 
phase behaviour, permeability, flip-flop and protein activity thereby modulating the local struc-
ture and function of cell membranes [54,62,64]. Although DHA is normally stored in mem-
branes as the fatty acid portion of certain phospholipids, free DHA has been also suggested 
to possess transcellular activity [65]. 
Various effects by DHA supplementation may be also due to a shift in eicosanoid formation. 
Thus, DHA is known to reduce PGE2 production [66] but also the expression of the PG syn-
thesising enzyme COX-2 [67,68]. Additionally, DHA enhances, probably in combination with 
EPA, the levels of COX and LOX driven mediators, e.g. resolvins, docosatrienes and pro-
tectins. These lipid mediators have been shown to act antiinflammatorily [69,70]. The 
mechanisms of such downstream events are complex and the antiinflammatory properties of 
DHA cannot be fully explained by a simple exchange of eicosanoid families [71]. 
Besides this, DHA is discussed to act via nuclear receptors, as it has been shown that DHA 
is e.g. a PPAR activator [54,72] as well as RXR ligand [73].  
 
Figure 7: Structure of DHA  
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1.4 Objective 
Due to the increased incidence and limited causal therapeutics allergic diseases have be-
come a major medical issue in the Western world [1]. The reasons of this development are 
not completely understood. In recent years research has pointed to the possible role of envi-
ronmental factors like changing Western dietary habits. The increased intake of n-6 PUFA 
(margarine, vegetable oil) and decreased n-3 PUFA (oily fish) consumption have been hy-
pothesised to contribute to this development. However, the associations with n-6 and n-3 
PUFA are complex and may differ between different allergic diseases [74,75].  
Although many immunomodulatory properties of DHA are described, the underlying mecha-
nisms of DHA action are not exactly understood. Therefore, the following objectives were 
investigated:  
• First, the target cells of antiallergic DHA action were identified and subsequently its mo-
lecular mechanisms investigated. 
• Within a randomised clinical study the therapeutical efficacy of high-dose DHA supple-
mentation was examined in patients with extrinsic atopic eczema. Beside the clinical ef-
fects, immunological parameters were analysed. 
• Finally, the clinical efficiency of oral DHA administration was verified in a mouse model of 
protein mediated eczema and the underlying local processes in eczematous skin exam-
ined in more detail. 
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2 Materials and methods 
2.1 Materials  
Equipment, software, commodities, chemicals, antibodies and buffer and solutions used are 
listed in detail in the appendix (page 94 - 105). 
2.2 Methods 
2.2.1 Donors and cells 
The in vitro experiments were approved by the ethical committee of the Charité–
Universitätsmedizin Berlin. Therefore, blood was obtained from allergic patients and healthy 
persons. 
Atopic donors were patients suffering from rhinoconjunctivitis allergica, asthma allergica and 
from atopic eczema defined according the criteria of Hanifin and Rajka [76] with serum IgE 
concentrations below 2500 ng/mL. Donors with allergic conjunctivitis, allergic rhinitis and 
asthma were recruited based on their history and positive prick testing as well as patients 
with atopic eczema from the Department of Dermatology and Allergy, Charité. 
None of the enrolled donors received a systemic immunosuppressive medication during the 
past three months before the blood sample was taken. Usage of topical steroids (class II-III) 
or antihistamines was not excluded. 
Blood samples from age and sex matched healthy volunteers (no type I allergies or positive 
family history of atopic diseases) and blood filters from blood donation of the Charité with IgE 
levels up to 100 ng/mL were chosen as control.  
2.2.2 Participants and clinical study  
The clinical study was approved by the ethical committee of the Charité–Universitätsmedizin 
Berlin and was performed in the Department of Dermatology and Allergy, Charité from Janu-
ary 2005 to June 2005. Written informed consent was obtained from each participant and 
eligibility was confirmed by a dermatologist.  
Patients suffering from atopic eczema aged between 18 and 40 years were enrolled into the 
study. Atopic eczema was defined according the criteria of Hanifin and Rajka [76]. Exclusion 
criteria were pregnancy, lactation, seafood allergies and consumption of dietary supplements, 
systemic immunomodulatory or immunosuppressive therapy in the last three months, pres-
ence of other systemic and chronic disorders than allergic diseases. Participants were al-
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lowed to use standard therapy for atopic eczema, including emollients, topical corticosteroids 
and oral antihistamines. Subjects were asked to maintain their habitual diet and activities 
throughout the intervention. Randomisation was stratified according to gender, age (cut off 
29 years) and body mass index (BMI; cut off 25 kg/m2) in a ratio of 1:1 using a randomised 
allocation schedule (based on block randomisation). Allocation concealment was assured by 
a sealed envelope up to finishing the data analysis. Recruited participants were randomly 
allocated to receive a treatment with either DHA capsules (n = 21) or control supplement 
(n = 23) by an independent clinician.  
Variable Control (n = 23) DHA (n = 21) 
Sex: female/male 16/7 14/7 
Age [years]: 26.7 [19.2 – 37.1] 26.5 [18.5 – 39.8] 
Height [cm]: 172.5 ± 8.5 173.8 ± 10.6 
Weight [kg]:  67.8 ± 13.3 72.5 ± 17.8 
BMI [kg/m2]: 22.7 ± 4.0 24.2 ± 5.2 
SCORAD: 35.4 [17.2 – 63.0] 37.0 [17.9 – 48.0] 
Total IgE [ng/mL] 983.9 ± 976.4 1336.1 ± 2135.0 
intrinsic/extrinsic type 4/19 6/15 
Table 1: Baseline characteristics of study population. 
Each participant was instructed to consume seven capsules daily (with main meals) for 
8 weeks. Every capsule contained 1 g of the respective oil. From DHA capsules, subjects 
consumed 5.35 g/d DHA and 0.37 g/d EPA in form of ethyl esters and control capsules pro-
vided 4.17 g/d caprylic acid (C8:0) and 2.84 g/d capric acid (C10:0). Participants were clini-
cally assessed at baseline (week 0), week 4 and 8 as well as 12 weeks after finishing the 
supplementation period (week 20) (Figure 8). The severity of atopic eczema was determined 
by Severity Scoring of Atopic Dermatitis (SCORAD) score through the same physician. At the 
first visit a full medical history was taken, physical examination was carried out and capsules 
were delivered. At every time point immunological parameters, i.e. anti-CD40/IL-4 stimulated 
IgE production, activation status of B cells and monocytes as well as cytokine production in 
peripheral blood mononuclear cells (PBMC) were analysed in our laboratories. Additionally, 
clinical safety was measured by laboratory parameters (liver enzymes, complete blood count 
and serum lipids). 
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Atopic eczema patients 
screened n = 77
1 patient
(non-compliance)
2 patients 
(hospital stay,
private reasons)
3 patients 
(non-compliance,
private reasons)
2 patients 1
week 0
randomly allocated (1:1) 
Strata: gender, age, BMI
n = 53DHA group
n = 28
control group
n = 25
week 4
week 8
week 20
exclusion because of drastic changes in clinical outcome 
due to external reasons 1 patient  2
control group
n = 23
DHA group
n = 21
24 patients failed to 
meet inclusion criteria
 
Figure 8: Study flow chart. Exclusion because of 1 unwanted interruption of the allowed 
standard medication leading to a drastic aggravation and 2 excessive sunbathing during holi-
days. 
2.2.3 Mouse model of allergen induced eczema 
Female BALB/c mice (8 to 10 weeks) were purchased from the Federal Institute of Risk As-
sessment, Berlin, Germany. All mice were kept within an accredited animal facility at the 
Charité-Universitätsmedizin Berlin and maintained under specific pathogen free conditions at 
controlled room temperature (21 ± 1°C), constant relative humidity (55 ± 5 %) and 12 hour 
light / dark cycle. Procedures were performed in compliance with protocols approved by the 
local State Office of Health and Social Affairs. 
As shown in Figure 9, mice were sensitised intraperitoneally (i.p.) on days 1 and 14 with 
100 µl of 10 µg OVA adsorbed to 1.5 mg Al(OH)3 or injecting phosphate buffered saline 
(PBS) as control. E.c. OVA application was performed by using patch test method as previ-
ously described [45]. Briefly, mice were anaesthetised with an i.p. injection of Ketamin / Rom-
pun. The dose was adapted according to body weight and application rate. Each mouse was 
weighed and the appropriate volume was calculated. Afterwards, the belly skin was shaved 
and 100 µg OVA adsorbed to 1.5 mg Al(OH)3 or PBS was applied twice a week by patch test 
method. Each mouse had a total of three one-week exposures to the same skin site 
separated by two-week intervals without any application. For treatment evaluation non-
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sensitised mice were used as negative control and PBS patched mice were referred as patch 
control. 
On day 64 the phenotypical outcome was evaluated, animals were sacrificed by cervical dis-
location and samples were taken for further analysis. Skin biopsies were frozen by liquid ni-
trogen. Blood samples were centrifuged at 3200 g for 10 min at 4°C. Serum was stored at 
-80°C. 
analysis
OVA-Patch
day 1 7          14          21         28          35      42        49          56 63  64
OVA-PatchOVA-PatchOVA-Injections
DHA supplementation
 
Figure 9: Sensitisation schedule for protein induced dermatitis and oral DHA appli-
cation in mice. Mice were sensitised i.p. with 10 µg OVA / alum at days 1 and 14 (black ar-
rows) and by e.c. patches with 100 µg OVA / alum (grey lines) with a total of three one-week 
exposures to the same skin site separated by two-week intervals without any application. 
Dietary DHA was applied during the whole experimental period. The e.c. sensitisation com-
prised three one-week exposures. On day 64 mice were sacrificed and samples were col-
lected. 
2.2.3.1 Diet 
During sensitisation mice were treated with standard solid food for rats and mice 
(Ssniff®Spezialdiäten, Soest, Germany) containing 2 % or 4 % DHA. Admixture of fatty acid 
blend, pellet forming and packing were performed by Ssniff® under cold and air-tight condi-
tions. Therefore, 4 % of DHA500TG and 5.7 % of DHA700EE was added to standard solid 
food to adjust 2 % and 4 % DHA in diet, respectively (Table 2). The basic food of control and 
experimental diet was originated from the same charge. The different diets were stored dark 
and protected from oxygen. Food and water were administered ad libidum. Nevertheless 
consumption was monitored. 
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Treatment group Control 2 % DHA 4 % DHA 
Fatty acid Composition [%] Composition [%] Composition [%] 
C14:0 0.3 n.d. n.d. 
C16:0 1.5 n.d. n.d. 
C16:1 0.3 n.d. n.d. 
C18:0 2.5 3.7 0.1 
C18:1 19.1 6.9 1.4 
C18:2 5.5 1.6 0.2 
C18:3 n-3 7.1 0.2 0.1 
C18:3 n-6 0.3 0.5 n.d. 
C18:4 n-3 0.6 0.3 0.1 
C20:4 n-6 n.d. 2.8 1.8 
C20:4 n-3 n.d. 0.7 0.5 
C20:5 n-3 (EPA) n.d. 8.3 5.6 
C22:5 n-3 n.d. 3.1 3.5 
C22:6 n-3 (DHA) n.d. 57.5 76.4 
Table 2: Fatty acid composition of lipids in experimental diet; n.d. - not detectable. 
2.2.3.2 Clinical Evaluation 
Evaluation of severity of OVA induced eczematous skin lesions was performed by a skin 
scoring system, which considers typical skin features of human atopic eczema, erythema, 
edema / papulation, excoriation / crusting, dryness and extension [76,77]. The total clinical 
skin score (CSS) was initially described in a murine model with spontaneous manifestation of 
atopic eczema like skin lesions [78]. For calculating total CSS, parameters were graded as 
0 (none), 1 (mild), 2 (moderate), and 3 (severe) by two independent observers. The total 
score was taken as index of dermatitis severity ranging from 0 (no skin lesion) to 15 (severe 
skin lesion) (Figure 10). 
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Figure 10: Illustration of total CSS according to clinical outcome: A) None, B) mild, 
C) moderate and D) severe protein induced eczema. For calculating total CSS, clinical pa-
rameters (erythema, edema / papulation, excoriation / crusting, dryness and extension) were 
graded as 0 (none), 1 (mild), 2 (moderate), and 3 (severe) by two independent observers. 
The total score was taken as index of dermatitis severity ranging from 0 (no skin lesion) to 15 
(severe skin lesion). 
2.2.4 Cell culture methods 
To ensure sterility, all cell isolation and culture procedures were performed under flow bench 
and with sterile / autoclaved commodities and reagents.  
2.2.4.1 Cell isolation methods 
Human PBMC were isolated by density gradient centrifugation with ficoll hypaque isolation 
(d = 1.077 g/mL) at 300 g, 20 min, room temperature. 
B cells were purified by magnetic cell sorting (MACS) using anti-CD19-coupled magnetic 
beads. Briefly, 2×108 PBMC were incubated in 300 µL MACS buffer and 100 µL autologous 
serum for 1 min, followed by 12 min of incubation with 100 µL beads at 4°C. CD19+ B cells 
were separated by magnetic double positive selection with the autoMACS. The purified cell 
population contained more than 99% B cells as assessed by flow cytometry. In previous stud-
ies, this procedure has been shown not to activate B cells [79]. Cell count measurements of 
the single cell suspensions were performed with CASY® cell counter. 
2.2.4.2 Cell culture conditions 
All cell cultures were carried out at 37°C in humidified air and 5 % CO2 atmosphere. The cul-
ture medium RPMI1640 was supplemented with L-glutamine (2 µM), penicillin (100 U/mL), 
streptomycin (100 µg/mL) and 10 % heat inactivated fetal calf serum (FCS), with the excep-
tion of analysis of STAT6 phosphorylation and NFκB translocation which was performed in 
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pure RPMI1640. DHA, dissolved in 100 % ethanol, was portioned and stored at -20°C for a 
maximum of six months. The vehicle control was performed in culture media containing the 
same volume of ethanol (0.001 %). Toxic effects of DHA were excluded by propidium iodide 
and trypan blue staining. 
2.2.4.3 Carboxy-fluorescein diacetate, succinimidyl ester (CFSE) labelling 
B cells were suspended in PBS containing 5 µM CFSE for 5 min at room temperature and 
subsequently washed. Cells were stimulated with anti-CD40 (1 µg/mL; 82111) and IL-4 
(5 ng/mL) [80] and were treated with 0.1 µM, 1 µM and 10 µM DHA. If not otherwise men-
tioned, CD40 ligation was mediated by clone 82111 at 1 µg/mL. Analysis by means of flow 
cytometry was performed on day 6. 
2.2.4.4 WST-1 assay  
For studies of cell mitochondrial activity WST-1 assay was performed. Briefly, 105 PBMC 
were cultured for 4 days and stimulated with anti-CD40/IL-4. 10 µL WST-1 reagent was 
added during the last 3 hours of culture to each well. Cellular enzymatic activity was deter-
mined by photometrical measurement at 450 nm. Cells treated with 0.1 µM, 1 µM and 10 µM 
DHA were compared with DHA untreated samples. Phorbol-12-myristate-13-acetate (PMA, 
10 ng/mL) was used as positive control. All experiments were performed in triplets. 
2.2.5 Immunological methods 
2.2.5.1 Enzyme-Linked Immuno Sorbent Assay (ELISA) 
ELISA was used to quantify immunoglobulins. Thereby, the unknown amount of antigen is 
bound to a surface by a primary antibody. The secondary antibody is incubated over this sur-
face so that it can bind specifically to the antigen. This detection antibody is linked to an en-
zyme, which converts a chromogenic substrate to some detectable signal. In case of antigen 
specific immunoglobulin determination primary or secondary antibody is replaced by the spe-
cific antigen. The amount of protein in the sample was calculated by means of standard 
curve. If not otherwise mentioned all steps were performed at room temperature. 
2.2.5.1.1 Human immunoglobulin ELISA 
For immunoglobulin assays cells (106/mL) were cultured for 10 days. Cells were stimulated 
with anti-CD40/IL-4 [80] and were treated with 0.1 µM, 1 µM and 10 µM DHA. After 10 days 
immunoglobulins were measured in cell free supernatants by ELISA. For IgE detection 
clones HP6061 and HP6029 were applied. The matched antibody pairs for IgA, IgG and IgM 
ELISA (anti-IgA, anti-IgG and anti-IgM) were purchased from Dianova. Immunoplates (maxi 
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Sorb) were coated overnight at 4°C with the primary antibodies for IgE clone HP6061 
(2.5 µg/mL) or for the other immunoglobulins (0.4 µg/mL) diluted in sodium carbonat buffer. 
Unspecific binding was prevented by adding 2 % bovine serum albumine (BSA) / Tris-
buffered saline (TBS) for 1 hour. Supernatants and standards were then incubated for 2 
hours. After washing, the second alkaline phosphatase conjugated anti-immunoglobulin anti-
body (0.15 µg/mL diluted in 0.2 % BSA/TBS) was added for 1.5 hours. Since the secondary 
mouse anti-human IgE antibody was biotinylated (HP6029, 0.5 µg/mL diluted in 0.2 % 
BSA/TBS) another hour of incubation with alkaline phosphatase conjugated streptavidin 
(1.5 µg/mL) was performed. Following the final reaction with phosphatase substrate, plates 
were read in a microplate ELISA reader at 405 nm and the amount of immunoglobulin was 
calculated according to the standard curve. Diluted human serum of an atopic individual 
served as standard curve. The sensitivity of the ELISA was 100 pg/mL. 
2.2.5.1.2 Murine immunoglobulin ELISA  
Plates were coated overnight with anti-mouse IgE (EM95.3, 5 µg/mL) diluted in sodium car-
bonate buffer. After blocking with 3 % milk powder/PBS, sera (diluted in 1 % milk pow-
der/PBS) were incubated overnight and were detected with biotin conjugated anti-mouse IgE 
(84 1-C, 1 µg/mL diluted in 1 % milk powder/PBS). The reaction was developed with strepta-
vidin peroxidase and tetra methyl benzidine and was stopped with 2 N sulphuric acid. The 
plates were measured at 450/490 nm and total IgE was calculated according to the standard 
curve. The monoclonal antibodies EM95.3 and 84 1-C were kindly provided by Dr. Elke Lu-
ger, DRFZ, Berlin, Germany / Dr. Lamer, MPI, Freiburg, Gemany. 
For measurement of OVA specific immunoglobulins plates were coated overnight either with 
rat anti-mouse IgE (R35-72, 2 µg/mL) or 5 µg/mL OVA for IgG1 and IgG2a in sodium carbon-
ate buffer. After blocking with 3 % milk powder/PBS, serial dilution of sera in 1 % milk pow-
der/PBS were incubated overnight, detected with biotin conjugated OVA (1.25 mg/mL, cou-
pling rate 1:50) for IgE, with rat anti-mouse IgG1 (A85-1, 0.5 µg/mL) or rat anti-mouse IgG2a 
(R19-15, 0.5 µg/mL) in 1 % milk powder/PBS and developed as mentioned above. Plates 
were read in a microplate ELISA reader at 450/490 nm. OVA specific immunoglobulin con-
centrations were calculated according to the standard serum pool.  
The validity of ELISAs was verified for total IgE by using serial sera dilutions and a standard 
of known concentration and for OVA specific immunoglobulins by using serial sera dilutions 
as well as by the determination of the semimaximal saturation. 
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2.2.5.2 Enzyme Linked Immuno Spot Technique (ELISpot) 
The number of antibody secreting cells was determined by ELISpot technique. Therefore, 
B cells were stimulated with anti-CD40/IL-4 in the presence of 0.1 µM, 1 µM and 10 µM DHA 
for 7 days. 106 B cells were cultured for IgA and IgG, whereas 3x106 cells were used for IgE 
ELISpot. MultiScreen-High Protein Binding Immibilion-P Membrane plates were coated over-
night with mouse anti-human IgE (HP6061, 2.5 µg/mL) and with goat anti-human IgA or IgG 
(0.4 µg/mL, Dianova) in sodium carbonate buffer. Unspecific binding was blocked by adding 
2 % BSA/PBS for 1 hour. After several washings, serial dilutions of B cells from 7 day cul-
tures were incubated at 37°C for adequate period of time. After washing, detection was per-
formed with biotin conjugated antibodies: mouse anti-human IgE (HP6029, 1.5 µg/mL), 
mouse anti-human IgA (G20-359, 5 µg/mL) or mouse anti-human IgG (G18-145, 0.1 µg/mL) 
in 0.2 % BSA/PBS. The reaction was developed with streptavidin-horseradish peroxidase 
(0.75 µg/mL) and peroxidase substrate 33-Amino-9-ethyl-carbazole/ n,n-Dimethyl formamide. 
Antibody secreting cells appeared as red spots and were counted with CTL ImmunoSpot® 
S4. 
2.2.5.3 Flow cytometry 
Fluorescence activated cell sorting (FACS) enables the analysis of single cells due to their 
characteristical light scattering and their emitted fluorescence. By the mean of forward light 
scatter (FSC) / side light scatter (SSC) characteristics, i.e. size and granularity, it is possible 
to distinguish between different cell populations. Analysis of specific intracellular and ex-
tracellular antigens can be performed by staining with fluorescence dye (e.g. FITC [Fluo-
resceine isothiocyanat], PE [Phycoerythrine], APC [Allophycocyanine]) coupled antibodies. In 
flow cytometer these dyes are excited by appropriate laser and subsequently emit light of 
different wave lengths. This emission is measured by defined detectors and is depicted in a 
graph as intensity per cell (Figure 11).  
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Figure 11: Exemplary flow cytometry images. A) FSC / SSC characteristics of B cells 
after 7 days of stimulation with anti-CD40/IL-4/IL-21, B) dot blot of anti-CD27 plus anti-CD38 
stained, C) histoblot of anti-CD27 stained and D) dot blot of anti-CD38 plus anti-IgE stained 
B cells. 
2.2.5.3.1 Flow cytometric analysis of PBMC activation 
Within the clinical trial the effect of DHA supplementation on activation status of PBMC iso-
lated cells was investigated. Therefore, isolated PBMC were stained with a combination of 
fluorescence dye labelled monoclonal antibodies. Antibodies used were anti-CD19 (4G7), 
anti-CD14 (MφP9), anti-CD23 (EBVCS-5) and anti-HLA-DR (Human Leukocyte Antigene-DR, 
L243). Staining was performed for 15 min at 4°C in the dark. 
2.2.5.3.2 Flow cytometric analysis of cytokines in PBMC  
Further on, the interference of DHA supplementation with systemic cytokine response was 
investigated in PBMC of treated patients. Therefore, 2x106 PBMC were cultured in the pres-
ence of Staphylococcus Enterotoxine B (SEB; 1 µg/mL) and anti-CD28 (L293, L25; 
0.2 µg/mL) or without any stimulation for 24 hours. To accumulate synthesised proteins in-
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tracellularly, 1 µg/mL Brefeldin A was added 4 hours before expiration of the incubation. After 
harvesting, cells were stained with fluorescence dye labelled monoclonal anti-human CD4 
(SK3) and anti-CD69 (L78) for 15 min at 4°C in the dark. After the following washing step, 
PBMC were fixed with 2 % paraformaldehyde (PFA) for 15 min at room temperature. Staining 
of intracellular cytokines was performed with anti-human IFNγ (4S·B3) and anti-IL-4 (8D4-8) 
in 0.5 % saponin / FACS buffer for 35 min at 4°C. Cells were immediately analysed at the 
flow cytometer. At least 100000 gated cells were collected for each sample. 
2.2.5.3.3 Flow cytometric analysis of STAT6 phosphorylation 
Within the scope of in vitro investigations, the impact of DHA on the IL-4 signalling pathway 
STAT6 phosphorylation was investigated by flow cytometry. After starving in the presence of 
0.1 µM, 1 µM and 10 µM DHA overnight, isolated B cells were stimulated with 10 ng/mL IL-4 
for 1 hour and harvested into BD Phosflow Fix Buffer I according to manufacturer’s instruc-
tions. Unstimulated cells were harvested in a similar fashion. After fixing the cells for 10 min 
at 37°C, B cells were permeabilised with Phosflow Perm Buffer III for 30 min on ice. After 
washing, cells were stained with anti-pSTAT6 (pY641; clone 18), anti-STAT6 (clone 23), 
anti-CD27 (LG.7F9) and anti-CD38 (HIT2) for 1 hour at room temperature. Cells were imme-
diately analysed at the flow cytometer. At least 30000 gated B cells were collected for each 
sample and geometric mean fluorescence was analysed. 
2.2.5.3.4 Flow cytometric analysis of IκBα degradation 
IkBα degradation was measured by flow cytometry to disclose the mechanisms of DHA me-
diated inhibition of p50 translocation. CD19+ B cells were preincubated with 0.1 µM, 1 µM 
and 10 µM DHA for 2 hours followed by a stimulation with 1 µg/mL anti-CD40 (G28.5) for 
1 hour. Subsequently, stimulated and unstimulated cells were harvested directly into 4 % 
PFA. After fixing the cells for 10 min at 37°C, B cells were incubated for 15 min with 
anti-CD20 (2H7), anti-CD27 (LG.7F9) and anti-CD38 (HIT2) on ice. After an additional wash-
ing step, cells were stained with anti-IκBα (L35A5) in 1 % saponin / FACS buffer for 30 min at 
4°C. Cells were immediately analysed at the flow cytometer. At least 30000 gated B cells 
were collected for each sample and geometric mean fluorescence was analysed. 
2.2.5.4 Immunohistochemistry 
Using biopsy punches, 5 mm diameter sections were obtained from patch areas of murine 
bellies, embedded in freezing medium and carefully frozen into liquid nitrogen. The tissue 
was cut into 5 µm specimens by a microtome at about -30°C and directly transferred on mi-
2 Materials and methods 
 
 
40
croscope slide. After drying on a hot plate, samples were stored at -80°C until further prepa-
ration. 
2.2.5.4.1 Staining of CD4+ and CD8+ T cells 
Initially, unspecific binding was blocked by using 5 % goat serum in TBS for 20 min and ap-
plication of the Avidin / Biotin Blocking Kit according to manufacturer’s instructions. After 
1 hour of incubation with rat anti-mouse CD4 (L3T4, 15 µg/mL, Figure 12A) or CD8 (53-6.7, 
15 µg/mL, Figure 12B), sections were exposed to biotinylated goat anti-rat IgG over 30 min. 
Staining was developed using Dako REAL™ Detection System Alkaline Phosphatase / RED. 
Thereby, alkaline phosphatase is covalently bound to biotin of secondary antibody by a strep-
tavidine bridge. The subsequently converted substrate designates the positive cells. Haema-
toxylin was used for nuclei counterstaining. This staining is based on the building of chelate 
rings of haematin plus salts with phosphate groups of nucleic acid in nucleus. The whole 
specimen was afterwards mounted on glass slides with preheated Kaiser's glycerin jelly. All 
steps were performed at room temperature. 
2.2.5.4.2 Mast cell staining 
To visualise MC granula filled with heparin and histamine (metachromatic), samples were 
stained with 0.1 % toluidine blue in 0.5 N HCl for 1 hour followed by short washing step with 
tap water (Figure 12C). 
2.2.5.4.3 Measurement of epidermal thickening 
Thickness of epidermis was determined by Axiovision measuring tools on the Axioplan light 
microscope at x100 magnification. The measurement included the stratum granulosum, stra-
tum spinosum and stratum basale. Since stratum corneum was partly damaged due to the 
procedure of fixing and slicing of the skin, its thickness could not be determined in all cases 
and was therefore excluded. For each mouse, eight measurements were obtained (Figure 
12D). 
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Figure 12: Illustration of histological analysis of protein induced dermatitis in 
BALB/c mice. Cell infiltrates of A) CD4+, B) CD8+ and C) MC as well as D) skin thickness 
were determined in 5 µm section of frozen skin samples. Positive immunohistochemical 
stained cells were counted in 100 µm x 200 µm areas at x100 magnification using the meas-
uring tools of Axiovision software. Skin thickness (µm) was determined in haematoxylin 
stained skin site by digital measurement tools.  
2.2.5.4.4 Quantification of cellular infiltrates 
To record dermal infiltration of CD4+, CD8+ cells and MC, positive stained cells were counted 
in 100 µm x 200 µm areas at x100 magnification using measuring tools of Axiovision soft-
ware. Only cells in the dermis were counted by positioning the square lengthwise on the bor-
der of epidermis and dermis. The mean of eight sections per mouse was calculated. 
2.2.6 Molecular biological methods 
For gene expression analysis real-time reverse-transcriptase (RT) polymerase chain reaction 
(PCR) was performed. Therefore RNA was isolated, transcribed into complementary DNA 
(cDNA) and finally analysed by quantitative PCR. 
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2.2.6.1 RNA isolation 
For analysis of εGLT and AID mRNA expression 106 B cells were stimulated with anti-CD40 
and / or IL-4 in the presence of 0.1 µM, 1 µM and 10 µM DHA for 4 days.  
RNA isolation of single cell suspensions was performed using RNA isolation kit Nucleo-
spin®RNA II according to manufacturer’s guidelines. This technique bases on a two column 
system. The first shredder column removes firm components from nucleic acids and the sec-
ond column binds nucleic acids. Salts, metabolites and macromolecular cellular components 
are removed by several washing steps with different buffers. 
Briefly, 106 cells were directly lysed by adding 350 µL RA1 buffer with 1 % beta mercapto 
ethanol. This lysis buffer immediately inactivates RNases and generates optimal conditions 
for adsorption of RNA to the silica membrane. Contaminating DNA was removed by a 15 min 
rDNase digestion. After numerous washing steps, RNA is eluted in RNase free water and its 
concentration is photometric measured at 260 nm in ND-1000 Spectrophotometer. To 
achieve higher RNA concentrations, the visible dye labeled carrier Pellet Paint™ Co-
Precipitant was used in combination with alcohol precipitation method. Pellets were resus-
pended in RNase free water for cDNA synthesis. 
2.2.6.2 cDNA synthesis 
Synthesis of cDNA was performed with Taq Man Reverse Transcription Reagent according to 
manufacturer’s instructions. This kit contains MultiScribe® Reverse Transcriptase, a recom-
binant Moloney Murine Leukemia Virus Reverse Transcriptase, random hexamers and oligo 
(dT). Finally, cDNA was stored at -20°C. 
2.2.6.3 Quantitative PCR 
For gene expression analysis real-time RT-PCR was performed. After thermal denaturation of 
double stranded DNA into single stranded DNA (95°C), oligonucleotides (primer) can com-
plementarily hybridise to a specific sequence on each strand of the target DNA at a primer 
dependent “annealing” temperature (60 to 65°C). Afterwards, a thermo stable DNA poly-
merase prolongs the oligonucleotides (72°C). The newly generated DNA sequence matches 
the sequence following the primer. After synthesising new DNA, the same primers will be 
released and used again. This gives DNA a logarithmic amplification.  
By the mean of double stranded DNA binding dye chemistry the amplicon production was 
quantified by using a non-sequence specific fluorescent intercalating agent. SYBR Green is a 
fluorogenic minor groove binding dye that does not bind to single stranded DNA. This dye 
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emits a strong fluorescent signal upon binding to double stranded DNA whereas it exhibits 
only little fluorescence in solution. Thus, as PCR products accumulate, fluorescence in-
creases. Real-time PCR monitors the fluorescence emitted during the reaction as an indica-
tor of amplicon production during each PCR cycle, i.e. in real time. Melting curve analysis 
was used to identify the specific amplicon and to exclude non-specific amplifications. All 
samples were measured at least in duplicates. Water was used as negative control. 
The used oligonucleotides (primer) were designed by means of the internet databases UCSC 
and NCBI and created by online software Primer3 (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). The required parameters for well designed primers and sam-
ples have been documented and are built into the program. These parameters include a 
melting temperature for the sample that is 10°C higher than the primers, primer melting tem-
perature about 60°C, amplicon size between 80 and 150 bases, absence of 5' guanosines 
and primer length between 20 and 25 nucleotides. The best design for primers for the quanti-
fication of mRNA expression requires intron spanning positioning. To achieve most optimal 
and specific results, PCR conditions were optimised regarding primer concentration, anneal-
ing temperature and time, magnesium chloride concentration as well as elongation time. The 
depicted primers are applied at a hybridisation temperature of 65°C and at concentration of 
500 nM (Table 3). 
Gene 5’ - 3’ Sequence 
amplicon 
[bp] 
MgCL2 
[mM] 
Efficiency E 
HPRT for TggCTTATATCCAACACTTCgTg 187 4 2.00 
HPRT rev ATCAgACTgAAgAgCTATTgTAATgACCA    
εGLT for gACgggCCACACCATCCACAggCAC-
CAAATggACgAC 
409 5 1.91 
εGLT rev CAggACgACTgTAAgATCTTCACg    
AID for AgAggCgTgACAgTgCTACA 93 4 1.88 
AID rev ATgTAgCggAggAAgAgCAA    
Table 3: Used oligonucleotides (primer) for quantitative real-time PCR. 
For quantitative real-time PCR LightCycler-Fast Start Master SYBR Green I was used ac-
cording to manufacturers’ guidelines. The reaction volume was reduced to 5 µL per sample.  
While reaction mass is denaturating for 10 min at 95°C, hot start polymerase is activated in 
the LightCycler unit. The measurement of the fluorescent signal is performed directly after 
elongation by polymerase. Thus, amplification progress can be detected simultaneously with 
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intercalation of SYBR Green. Amplification of a given cDNA over time follows a curve, with an 
initial flat phase, followed by an exponential phase. As the experiment reagents are used up, 
DNA synthesis slows and exponential curve flattens into a plateau. For the RT-PCR principle, 
the more cDNA is in a sample, the earlier it will be detected during repeated cycles of ampli-
fication.  
Target gene levels were normalised to a housekeeping gene as an endogenous control, to 
correct potential variation in RNA loading, cDNA synthesis or efficiency of the amplification. 
Expression levels of reference genes should remain roughly constant between cells of differ-
ent tissues and under different experimental conditions. Here hypoxanthine guanine phos-
phoribosyltransferase (HPRT) was used to evaluate expression of target genes. 
The comparative CP method for analysis involves comparing the threshold cycle or crossing 
point (CP) values of samples of interest with a control. The relative expression ratio (R) of a 
target gene is based on the real-time efficiency (E) of the primer pair, the CP deviation of an 
unknown sample versus a control and is expressed in comparison to a reference gene (ref) 
(Formula 1). Either DHA untreated sample in in vitro experiments or control diet fed mice 
were set as control. Efficiency corrected relative quantification was performed by 2-∆∆CP 
method [81].  
sample)-lref(controC
ref
sample)-troltarget(conC
target
P
P
)(E
)(E
∆
∆
=R
 
Formula 1: ∆∆CP method for mRNA quantification. 
2.2.6.4 Western blot 
The western blot technique enables the detection of a specific protein in a given sample ho-
mogenate or extract. Primarily, gel electrophoresis is used to separate native or denatured 
proteins by the length of the polypeptides. The proteins are transferred afterwards to a mem-
brane (typically nitrocellulose or polyvinylidene difluoride [PVDF]), where they are detected 
using antibodies specific for target protein. Here, western blot is used to investigate the im-
pact of DHA on the NFκB signalling by the means of p50 translocation into nucleus.  
After 2 hours preincubation with 10 µM DHA, isolated B cells were stimulated with 1 µg/mL 
anti-CD40 (G28.5) for 1 hour. Protein extracts of 5x106 B cells were prepared by NE-PER 
extraction reagent containing a protease inhibitor cocktail and were subsequently quantified 
by standard coomassie plus protein assay according to manufacturer’s instructions. Nuclear 
2 Materials and methods 
 
 
45
extracts (3 to 5 µg) were separated in a 12 % tris glycine sodium dodecyl sulfate (SDS) poly-
acrylamide gel. Proteins were transferred to PVDF membrane and blocked for 1 hour with 
5 % milk powder/PBS. Overnight membrane was incubated with 0.2 µg/mL anti-human p50 
(H119) in 1 % milk powder/PBS-Tween (PBST) at 4°C. After washing the membrane with 
PBST, horse radish peroxidase (HRP) conjugated goat anti-rabbit IgG (0.1 µg/mL in 1 % milk 
powder/PBST) was added for 1 hour at room temperature. The antigen detection was per-
formed with the chemiluminescent detection system ECL Plus. 
2.3 Statistical analysis 
Wilcoxon test for non-parametrical, paired data using SPSS (Statistical Package for the So-
cial Sciences) software package for Windows, Release 12.0 and 14.0 was carried out to ana-
lyse the statistical significance of within-group changes. Non-parametrical, unpaired data was 
analysed by Mann-Whitney U-test to evaluate the significance of between group changes. A 
p-value < 0.05 was considered to be statistically significant.  
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3 Results 
3.1 DHA inhibits IgE production in human B cells 
3.1.1 Modulation of immunoglobulin synthesis  
3.1.1.1 DHA inhibits anti-CD40/IL-4 mediated IgE production in B cells 
To investigate the impact of DHA on IgE production, PBMC and B cells were analysed re-
garding IgE production and number of IgE secreting cells using ELISA and ELISpot, respec-
tively. For better illustration DHA untreated stimulated sample was set as 100 %. 
IgE production from PBMC of non-allergic donors was negligible (< 20 pg/mL). After 
anti-CD40/IL-4 stimulation, in supernatants IgE increased up to 7378 ± 4475 pg/mL 
(p = 0.028). DHA treatment led to a dose-dependent reduction of IgE production. 10 µM DHA 
was most efficient to inhibit reaching 714 ± 382 pg/mL (p = 0.028) (Figure 13A).  
PBMC of allergic donors showed a basal IgE production up to 3400 pg/mL which was in-
creased by anti-CD40/IL-4 stimulation to 16206 ± 3758 pg/mL (p = 0.028). Regarding their 
response to DHA treatment two subgroups among atopic patients were identified. PBMC 
from donors with a high basal IgE production (IgE > 1000 pg/mL) did not respond to DHA 
(data not shown). In contrast, in PBMC cultures of donors with basal IgE production lower 
than 1000 pg/mL DHA caused a dose-dependent reduction of IgE production as noticed in 
cultures of healthy individuals. Thereby, 10 µM DHA caused the strongest reduction to 
1182 ± 838 pg/mL (p = 0.028) (Figure 13A).  
Next it was investigated whether the inhibition of IgE was due to direct action of DHA on 
B cells. After anti-CD40/IL-4 stimulation, IgE production of B cells increased up to 25-fold 
(2270 ± 1610 pg/mL, p < 0.001) and was dose-dependently inhibited by DHA treatment. The 
highest DHA concentration caused the strongest inhibition as measured with 
485 ± 719 pg/mL IgE in supernatants (p < 0.001, Figure 13B). 
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Figure 13: DHA inhibits IgE production dose-dependently in anti-CD40/IL-4 stimu-
lated A) PBMC and B) B cells. Isolated PBMC or B cells were stimulated with 
anti-CD40/IL-4 for 10 days. IgE was determined in supernatants by ELISA. IgE production in 
% of anti-CD40/IL-4 stimulated, DHA untreated cells (100 %). Data are shown as box plot 
(25. and 75. percentile, median); n ≥ 6; * statistically significant difference compared to DHA 
untreated sample (* p < 0.05; *** p < 0.001). 
To delineate whether DHA interferes with the early switch machinery or the late immu-
noglobulin secretion process, DHA was added to B cell culture at different time points (days 
0, 2, 4, 6 and 8). The results show that DHA exerted the strongest IgE inhibition when added 
at the beginning of the culture. This inhibition was continuously decreasing if added at later 
time points (Figure 14). 
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Figure 14: DHA inhibits early switching. Experimental setting is described in Figure 13. 
10 µM DHA was added to B cell culture at different time points (days 0, 2, 4, 6 and 8). IgE 
production in % after treatment with 10 µM DHA relative to anti-CD40/IL-4 stimulated, DHA 
untreated sample (100 %). Data are shown as mean + SD; n = 3. 
Furthermore, IgA and IgG production was measured in supernatants to examine whether the 
inhibition of IgE was isotype specific. Indeed, DHA treatment did not alter IgA and IgG pro-
duction of cultured B cells (Figure 15).  
IgG IgA
0
50
100
150
Ig
pr
od
uc
tio
n 
in
 %
 o
f D
H
A
 u
nt
re
at
ed
 s
am
pl
e
Ig
pr
od
uc
tio
n 
in
 %
 o
f D
H
A
 u
nt
re
at
ed
 s
am
pl
e
 
Figure 15: DHA does not affect IgG and IgA production in B cells. Experimental set-
ting is described in Figure 13. Immunoglobulin (Ig) production in % after treatment with 
10 µM DHA relative to anti-CD40/IL-4 stimulated, DHA untreated sample (100 %). Data are 
shown as box plot (25. and 75. percentile, median); n ≥ 6. 
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3.1.1.2 DHA reduces the number of IgE secreting cells 
To prove that the reduced amount of IgE in supernatants was due to a reduced number of 
antibody secreting cells, ELISpot analysis was performed after 7 days culture. 
As depicted in Figure 16A, DHA treatment of B cell cultures caused a concentration-
dependent effect on IgE secreting cells. 10 µM DHA reduced significantly the number of IgE 
secreting cells (51 ± 34 %, p = 0.043). Interestingly, 0.1 µM DHA did not decrease, but rather 
increased IgE secreting cell numbers (139 ± 30 %, p = 0.043). 100 % correspond to 75 ± 79 
IgE secreting cells / 106 B cells. 
In contrast, DHA did not reduce the number of IgA secreting cells (Figure 16B). But, 
10µM DHA slightly reduced the number of IgG secreting cells to 91 ± 25 % of DHA untreated 
sample (p = 0.043, Figure 16C). 343 ± 284 IgG secreting cells / 106 B cells and 237 ± 180 
IgA secreting cells / 106 B cells represent 100 %. 
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Figure 16: DHA reduces the generation of A) IgE secreting cells in anti-CD40/IL-4 
stimulated B cells, whereas B) IgA was not affected and C) IgG was slightly reduced 
only at the highest DHA concentration. B cells were stimulated with anti-CD40/IL-4 for 
7 days. Number of antibody secreting cells was determined by ELISpot. Data are shown in % 
of anti-CD40/IL-4 stimulated, DHA untreated control (100 %), as mean ± SD; n ≥ 5; * p < 0.05 
statistically significant difference compared to anti-CD40/IL-4 stimulated, DHA untreated 
sample. 
Next, antiproliferative or toxic effects mediated by DHA were ruled out. As shown in Fig-
ure 17, DHA exerted no inhibition of B cell proliferation as measured by CFSE labelling. Fur-
thermore, toxicity by DHA was excluded by tryptan blue and propidium iodide staining. 
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Figure 17: DHA is not toxic or antiproliferative in B cells. A) Propidium iodide (PI) posi-
tive B cells after 10 days of stimulation with anti-CD40/IL-4 with or without DHA. Data are 
shown as box plot (25. and 75. percentile, median); n = 5. B) Mitochondrial metabolic activity 
after 3 days of stimulation with anti-CD40/IL-4 with or without DHA as measured by WST-1. 
Data are shown as mean ± SD; n = 8. C) CFSE division after 4 days of stimulation with 
anti-CD40/IL-4 in the presence or absence of DHA. Histogram is a representative of three 
independent experiments; n = 3.  
3.1.1.3 DHA reduces activation-induced (cytidine) deaminase (AID) mRNA expression 
Since AID is essential for isotype switching [17], the impact of DHA on its expression was 
determined next. 
As shown in Figure 18A, AID mRNA expression was induced by anti-CD40/IL-4 stimulation 
up to fivefold (p = 0.043) and decreased dose-dependently in DHA treated B cells. The 
strongest inhibition was detected when the highest DHA concentration was used (44 ± 32 %, 
p = 0.018). However, the overall inhibition was less prominent as DHA mediated εGLT inhibi-
tion. 
3.1.1.4 DHA inhibits IgE switch recombination  
Immunoglobulin heavy chain CSR correlates with the induction of specific germline CH tran-
scripts. The expression of εGLT precedes IgE production and indicates switching process 
towards IgE [82,83].  
In B cells εGLT expression was induced fivefold by anti-CD40/IL-4 stimulation (p = 0.043). 
The presence of DHA led to a dose-dependent reduction of εGLT expression. The maximal 
inhibition was observed with 10 µM DHA reaching 87 ± 13 % (p = 0.028) (Figure 18B).  
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Figure 18: DHA inhibits A) AID and B) εGLT expression in anti-CD40/IL-4 stimulated 
B cells in a dose-dependent manner. B cells were stimulated with anti-CD40/IL-4 and 
treated with DHA. After 4 days of incubation cells were harvested and AID and εGLT mRNA 
expression was determined using quantitative RT-PCR. Fold expression of anti-CD40/IL-4 
stimulated, DHA untreated control. Data are shown as box plot (25. and 75. percentile, me-
dian); n = 8; * p < 0.05 statistically significant difference compared to anti-CD40/IL-4 stimu-
lated DHA untreated sample.  
To delineate whether the IL-4 and / or the CD40 pathway was disrupted by DHA, B cells were 
stimulated with anti-CD40 or IL-4 alone. Thereby 10 µM DHA inhibited εGLT expression in-
duced by IL-4 (51 ± 31 %, p = 0.018) as well as by CD40 ligation (52 ± 1 %, p = 0.001) dose-
dependently (data not shown). 
3.1.2 DHA modulates IL-4 and anti-CD40 signalling 
3.1.2.1 DHA reduces STAT6 phosphorylation 
Since εGLT and AID were inhibited by DHA and their promoter regions contain IL-4 depend-
ent STAT6 and CD40 dependent p50 binding sites [5], DHA mediated IgE inhibition might be 
attributed to the modulation of CD40 and / or IL-4 signalling.  
IL-4 signalling regulates transcription of IL-4 responsible genes through STAT6 phosphoryla-
tion and dimerisation [9]. Phosphorylation of STAT6 (pSTAT6) in the presence of DHA was 
measured by flow cytometry. 
The basal phosphorylation level of STAT6 was low (mean fluorescence intensity [MFI] 
3.0 ± 0.6). Whereas IL-4 stimulation increased the number of pSTAT6 positive cells 50-fold 
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and the MFI threefold (11.0 ± 3.7, p = 0.008). As depicted in Figure 19, DHA reduced STAT6 
phosphorylation dose-dependently at 1 µM (MFI 9.3 ± 4.4, p = 0.022) and 10 µM DHA 
(8.1 ± 3.6, p = 0.008). However, 0.1 µM DHA did not affect STAT6 phosphorylation 
(11.6 ± 4.2, n.s.). 
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Figure 19: DHA inhibits phosphorylation of STAT6 dose-dependently in IL-4 stimu-
lated B cells. After starving in the presence of DHA overnight, B cells were stimulated with 
IL-4 for 1 hour. After fixing the cells, cells were permeabilised and stained with anti-pSTAT6, 
anti-STAT6, anti-CD27 and anti-CD38. At least 30000 gated B cells were collected for each 
sample. The geometric mean fluorescence intensity was analysed. A) Gating strategy; 
B) Data are shown as mean ± SD; n = 8; C) Representative histogram for DHA treatment; 
D) Representative histogram for dose-response analysis; * p < 0.05; ** p < 0.01 statistically 
significant difference compared to IL-4 stimulated, DHA untreated sample. 
This reduction was not restricted to B cell subsets as both naïve or memory B cells exhibited 
reduced STAT6 phosphorylation (data not shown). Concomitantly, a decreased ratio between 
STAT6 and pSTAT6 was measured (p = 0.018, Figure 20). Importantly, DHA treatment did not 
inhibit STAT6 protein expression of B cells.  
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Figure 20: DHA decreases pSTAT6 and STAT6 ratio. Experimental setting is described 
in Figure 19. Data are shown as mean ± SD; n = 8; * p < 0.05 statistically significant differ-
ence compared to IL-4 stimulated, DHA untreated sample. 
3.1.2.2 DHA decreases NFκB p50 translocation 
NFκB p50 is the most relevant downstream event of CD40 involved in isotype switching [15]. 
To analyse whether the detected impairment of IgE production is accompanied by a de-
creased p50 translocation, nuclear protein expression in DHA treated B cells was examined 
by western blot technique.  
As shown in Figure 21, p50 protein was detectable in nuclear extracts of unstimulated 
B cells. Stimulation with anti-CD40 caused the additional translocation of p50 into the nu-
cleus from 129 ± 20 to 177 ± 29 densitometric arbitrary units (p = 0.018). However, concomi-
tant treatment with 10 µM DHA inhibited anti-CD40 driven nuclear p50 translocation 
(125 ± 41 densitometric arbitrary units; p = 0.028). 
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Figure 21: DHA inhibits anti-CD40 induced p50 translocation into the nucleus in 
B cells. Isolated B cells were preincubated with 10 µM DHA for 2 hours and subsequently 
stimulated with anti-CD40 for 1 hour. Nuclear extracts were analysed by western blot. p50 
protein was detected at 50 kDa. A) Data are shown as single values, bars represent mean 
values. B) Blot is a representative of seven independent experiments (n = 7); * p < 0.05 sta-
tistically significant difference compared to anti-CD40 stimulated, DHA untreated sample. 
Finally, it was determined whether a modulation of IκBα degradation by DHA was responsi-
ble for the inhibited p50 translocation. The intracellular IκBα content decreased from a basal 
geometric MFI of 172 ± 19 to a MFI of 92 ± 26 upon anti-CD40 stimulation. These data rule 
out such a mechanism as DHA did not alter the anti-CD40 driven degradation of IκBα mea-
sured by flow cytometry (Figure 22). 
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Figure 22: DHA does not affect anti-CD40 driven IκBα degradation. Experimental set-
ting is described in Figure 21. B cells were stained with anti-CD20, anti-CD27, anti-CD38 and 
anti-IκBα. 30000 gated B cells were collected for each sample and the geometric mean fluo-
rescence was analysed. Data are shown as box plot (25. and 75. percentile, median); n = 6. 
3.2 DHA supplementation in atopic eczema – a randomised, double 
blind, controlled study 
According to the in vitro data, DHA caused a significant and dose-dependent inhibition of IgE 
production in anti-CD40/IL-4 stimulated PBMC and exhibited immunomodulating properties. 
Therefore, the therapeutic efficacy of dietary DHA was investigated in a randomised, con-
trolled and double blind clinical trial with atopic eczema patients. The tolerability of DHA was 
excellent. Only three participants reported slight gastrointestinal discomfort.  
3.2.1 The SCORAD is significantly reduced by DHA supplementation 
As shown in Figure 23, a significant reduction of the SCORAD was observed in the DHA 
treated group (p = 0.009), but not in the control group. However, in both groups an improve-
ment of SCORAD was detected. In the DHA group the assessed median decline of SCORAD 
was -18 % [-96 % - 29 %], whereas in the control group the SCORAD decreased 
-11 % [-84 % - 35 %] from baseline to week 8.  
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Figure 23: SCORAD is significantly reduced by dietary DHA. SCORAD was deter-
mined in control (n = 23) and DHA (n = 21) group during the course of supplementation by 
the same physician. Data are shown as box plot (25. and 75. percentile, median) [84]. 
The decreased SCORAD in the DHA group was mainly attributed to the significant reduction 
of affected areas from 12 [2 - 41] SCORAD points at baseline to 7 [2 - 25] at week 8 
(p = 0.02; data not shown). No change of individuals’ medication usage occurred during sup-
plementation.  
3.2.2 DHA inhibits IgE synthesis ex vivo 
Before and after supplementation the IgE production of stimulated PBMC was measured in 
order to determine the impact of fatty acid supplementation on IgE synthesis. At baseline IgE 
production in anti-CD40/IL-4 stimulated PBMC was comparable in both groups and de-
creased only during DHA treatment significantly (week 0: 10.62 ± 9.2 ng/mL; week 8: 
3.6 ± 3.1 ng/mL; p = 0.013; Figure 24). By contrast, no impact on ex vivo IgE production was 
detected in the control group (week 0: 7.0 ± 5.8 ng/mL; week 8: 5.1 ± 5.6 ng/mL; n.s.). By 
checking the proportions of CD14+, CD19+, CD4+, and CD8+ changes of anti-CD40/IL-4 me-
diated IgE synthesis due to an alteration of PBMC composition was excluded. However, the 
total IgE concentration measured in sera was not altered in both groups (data not shown). 
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Figure 24: Ex vivo IgE production is inhibited by dietary DHA. IgE production of 
anti-CD40/IL-4 stimulated PBMC before and after supplementation in the control (n = 23) and 
DHA group (n = 21). Therefore, isolated PBMC were stimulated with anti-CD40/IL-4 for 
10 days. IgE was determined in supernatants by ELISA. Data are shown as box plot (25. and 
75. percentile, median); * p < 0.05 statistically significant difference compared to baseline 
values. 
3.2.3  Fatty acid supplementation modulates activation of monocytes and B cells 
In both groups supplementation led to a significant modulation of the activation status of 
monocytes (CD14+), but also of B cells (CD19+), as determined by HLA-DR and CD23 ex-
pression, respectively. Thereby, proportion of CD14+HLA-DR+ and CD19+CD23+ decreased 
slightly in relation to the relevant cell population up to week 8. After termination of the sup-
plementation period, proportions increased up to initial values (data not shown). 
3.2.4 Systemic IFNγ and IL-4 response remains unaffected by fatty acid sup-
plementation 
Additionally, the impact of fatty acid supplementation on systemic cytokine production was 
investigated. Therefore, untreated or SEB/anti-CD28 stimulated PBMC were analysed re-
garding IFNγ and IL-4 production of activated CD69+ TH cells. In unstimulated PBMC a sig-
nificantly increased percentage of CD4+CD69+IL-4+ was determined whereas the proportion 
of CD4+CD69+IFNγ+ decreased at the basal level in both groups during intervention. In con-
trast, the cytokine production was not altered in SEB/anti-CD28 stimulated PBMC during 
supplementation. Solely a significant decline of CD4+CD69+IL-4+ was measured in control 
group (week 0: 0.31 ± 0.14 %; week 8: 0.21 ± 0.12 %; p = 0.016). However, no significant 
differences were detected between both groups (data not shown). 
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3.3 Oral administration of DHA inhibits the development of eczema in a 
murine model of protein induced dermatitis  
Immunological impact of oral administration of high dose DHA was investigated in a murine 
model of protein induced eczema. DHA containing diet was well consumed and no side ef-
fects were observed. All feeding groups showed a comparable development of body mass, 
liver and spleen weight.  
3.3.1 Dietary DHA reduces the clinical symptoms of protein induced dermatitis 
As shown in Figure 25, OVA patched mice developed local dermatitis with macroscopic clini-
cal symptoms, like dryness, erythema, edema, papules, oozing and crusts. Thereby initial 
systemic sensitisation was essential to elicit visible skin lesions in a significant response rate 
by e.c. OVA applications [85].  
A B C D
 
Figure 25: Improved severity of eczema in DHA fed mice. Representative illustration of 
protein induced dermatitis in mice fed with A) control diet, B) 2 % DHA and C) 4 % DHA in 
the diet. Picture D) illustrates the respective skin area of a non-sensitised control mouse.  
As graded by total CSS, e.c. OVA treatment strengthened clinical symptoms from a median 
of 4 [2 – 5] points in control patched mice (PBS/alum) up to 12 [5 – 12] points in OVA patched 
mice (p = 0.017) (Figure 26). In contrast non-sensitised mice revealed no skin lesions. Fol-
lowing DHA supplementation a significant reduction of CSS was determined compared to 
control fed diet. Interestingly, 2 % DHA supplemented diet was most effective to reduce the 
CSS to 7 [5 – 8] (p = 0.008), while in 4 % DHA group the outcome was ameliorated to 
8 [7 - 10] (p = 0.032).  
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Figure 26: Oral DHA administration reduces the clinical symptom score of protein 
induced eczema. Data are shown as box plot (25. and 75. percentile, median); n ≥ 5; 
* p < 0.05, ** p < 0.01 statistically significant difference compared control fed, OVA sensitised 
mice.  
3.3.2 Dietary DHA reduces the number of CD8+ T cells in eczematous skin 
In this murine model of protein induced dermatitis affected skin areas reveal histopathological 
features of eczema, such as epidermal thickening, parakeratosis, spongiosis and a dense 
perivascular infiltrate, accompanied by increased MC infiltration and degranulation. Immuno-
histochemical analysis demonstrates significant increase of dermal CD4+ and of CD8+ cells. 
The epidermal thickness was measured eight times per mouse and calculated as average 
value. In all feeding groups the same range of epidermal thickness was indicated, i.e. no im-
pact of DHA supplementation on this histological feature was assessed (data not shown).  
Cellular infiltrates were determined by counting immunohistochemically stained cells in eight 
sections (100 x 200 µm) per mouse. 
Toluidine blue stained MC were located in the dermis and subcutaneous tissue. The number 
of MC was almost equal in skin preparations of control fed mice and in DHA treated mice 
(data not shown). 
CD4+ cells were located in the dermis, but not in the epidermis. Under DHA treatment no 
significant alteration in number of infiltrated CD4+ cell was determined (data not shown). 
In comparison to CD4+ cells, only a few CD8+ cells were found in the dermis, but also in the 
epidermis. As depicted in Figure 27, less CD8+ cells (1.7 ± 0.5, p = 0.032) were detected in 
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dermis of 2 % DHA supplemented mice compared to sections of control fed mice (3.9 ± 2.1). 
Additionally, 4 % DHA supplementation tended to result in a reduced dermal CD8+ number 
(1.5 ± 1.0, n.s.), but failed to reach significance. 
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Figure 27: Oral DHA administration reduces the number of CD8+ T cells in eczema-
tous skin. Representative histological image of anti-CD8+ stained 5 µm sections of frozen 
skin from A) a PBS patched BALB/c mouse, from mice with protein induced dermatitis fed 
with B) control diet, C) 2 % DHA and D) 4 % DHA in the diet. E) Positive immunohistochemi-
cal stained cells were counted in 100 µm x 200 µm areas at x100 magnification using digital 
measuring tools. Data are depicted as box plot (25. and 75. percentile, median); n ≥ 5; 
* p < 0.05, ** p < 0.01 statistically significant difference compared control fed, OVA sensitised 
mice. 
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3.3.3 Oral DHA administration did not alter the systemic immune response  
To evaluate the immunomodulating efficacy of dietary DHA on the systemic immune re-
sponse, immunoglobulin concentrations were measured in sera by ELISA technique. Never-
theless, no significant impact of DHA treatment on total IgE, OVA specific IgE, IgG1 and IgG2a 
serum concentrations was determined (Table 4). 
Treatment w/o DHA 2 % DHA 4 % DHA negative control 
Total IgE [ng/mL] 2384 ± 1059 2427 ± 737 2793 ± 859 59 ± 48 (p = 0.024)
OVA specific IgE [LU/mL] 131 ± 30 144 ± 25 158 ± 32 n.d. (p = 0.031) 
OVA specific IgG1 [LU/mL] 6226 ± 1983 6460 ± 528 6899 ± 2109 n.d. (p = 0.031) 
OVA specific IgG2a [LU/mL] 1284 ± 894 871 ± 942 1161 ± 1276 n.d. (p = 0.031) 
Table 4: Oral DHA administration does not affect systemic immune response. Total 
IgE, OVA specific IgG1, IgE and IgG2a concentrations were analysed in sera of OVA sensi-
tised and OVA sensitised plus DHA fed mice by ELISA. Data represent mean ± SD; in brack-
ets: p as compared to control fed, OVA sensitised mice; negative control – non-sensitised 
mice; n.d. - not detectable.  
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4 Discussion 
The incidence of common allergic diseases has increased quite dramatically during the last 
decades and in many countries the prevalence has reached almost epidemic proportions [1]. 
At this time a cure for these diseases does not really exist, although a wide range of treat-
ments are used to control the symptoms. The costs are manifold including both, direct and 
indirect components [23]. Thus, allergies have become a major medical issue of the Western 
world. Since there is an indication that the nutritional factors, especially the changing dietary 
fatty acids may contribute to this alarming development, many investigations have been done 
in this field [74,75].  
The first evidence for relevance of dietary n-3 PUFA in inflammation was derived from epi-
demiological observations displaying a low incidence of autoimmune and inflammatory disor-
ders in a population of Greenland Inuit compared with gender and age matched groups living 
in Denmark [86]. Most of these diseases are designated by inappropriate activation of T cells 
and destruction of tissues. Interestingly, native Greenland Inuit [87] and Japanese [88] con-
sume high amounts of long chain n-3 PUFA from seafood and have a low incidence of 
chronic inflammatory or autoimmune disorders, even compared to their Westernised ethnic 
counterparts.  
It is very likely that DHA and EPA are responsible for the beneficial effects of fish oils on the 
immune system [53,89]. Until now the majority of studies dealing with the immunomodulatory 
effects of long chain n-3 PUFA have been dealing with fish oils, what limits the understanding 
of the particular effects of EPA and DHA and prohibits their comparison. There are still con-
troversial results regarding which n-3 PUFA is accountable for the effects of fish oil 
[90,91,92]. Thereby, DHA exerts a lot of favourable effects in many diseases and is known to 
be antiinflammatory. However, some researchers assume that DHA is the biologically active 
component of fish oil [93].  
4.1 DHA inhibits IgE production in human B cells  
Allergic individuals exposed to minute amounts of allergen experience an immediate immune 
response with possibly a fatal outcome. The spreading epidemic of allergies and atopic di-
seases has generated a great interest in IgE, the central molecule of type I allergic reactions. 
IgE is usually found at low concentrations in the plasma and mainly secreted by plasma cells 
in mucosa associated lymphoid tissue. Patients suffering from atopic disorders, like asthma, 
allergic rhinitis and extrinsic atopic eczema have elevated serum levels of both, total IgE and 
allergen specific IgE. The differentiation of a B cell to an IgE producing cell is tightly adjusted 
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via CSR [5,94]. Consequently, a potential target for prevention and treatment of atopic 
diseases by DHA is the regulation of IgE production, in particullar the switch towards IgE.  
To induce IgE synthesis in vitro, cells were stimulated with anti-CD40 and IL-4 [80]. Applica-
tion of DHA resulted in a dose-dependent inhibition of IgE production in both, PBMC and 
B cells. This effect was isotype specific since both, IgG and IgA remained unchanged. Toxic 
or antiproliferative effects were excluded using B cells labelled with CFSE and WST-1 assay 
as well as by staining with tryptan blue and propidium iodide for identification of dead cells.  
Furthermore, it was investigated if the reduced amount of IgE in supernatants was due to 
inhibition of immunoglobulin secretion, altered differentiation into IgE secreting plasma cells 
or a result of impaired switching towards IgE. 
DHA dose-dependently inhibited the anti-CD40/IL-4 driven differentiation to IgE secreting 
cells. However, the number of IgA secreting cells was not altered, excluding the possibility of 
a general inhibited immunoglobulin secretion and indicating IgE specific alteration of plasma 
cell differentiation. 
It was determined that DHA specifically interfered with the IgE switching process at the tran-
scriptional level of AID and εGLT. The importance of AID in CSR got obvious after rigorous 
impairment in AID-/- mice [95] as well as in patients with autosomal recessive hyper-IgM syn-
drome (HIGM2), who carry mutations in the AID gene [96]. However, DHA inhibited AID 
mRNA expression dose-dependently suggesting interference in AID dependent switch re-
combination. Interestingly, IgA and IgG remained almost unchanged regarding production 
and number of antibody secreting cells indicating that the dimension of DHA mediated AID 
inhibition was not sufficient to affect switch recombination in general. 
CSR towards IgE in B cells stimulated with anti-CD40/IL-4 involves a number of molecular 
events [97]. The transcription of εGLT precedes B cell IgE synthesis and the dependency of 
switching to IgE on its expression has been reported [83]. Consequently, the dose-dependent 
inhibition of εGLT points to the IgE specific action of DHA. Thereby, DHA caused this obvious 
inhibition of IgE by reducing εGLT transcription together with decreasing expression of AID.  
B cell IgE production is regulated by cytokines like IL-4 [98] as well as direct contact between 
B and T cells [99], especially by CD40/CD154 interaction [80]. Importantly, AID [100] and 
εGLT [101] are dependent on IL-4 and CD40, whose downstream signalling is mediated 
through STAT6 and NFκB. Since DHA downregulated εGLT expression in B cells stimulated 
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with anti-CD40 or IL-4 alone, the involved signalling pathways were examined by analysis of 
STAT6 phosphorylation and NFκB p50 translocation into nucleus. 
Preincubation of B cells with DHA caused a dose-dependent inhibition of STAT6 phosphory-
lation. The analysis of the total STAT6 protein revealed no impact of DHA, but a decreased 
pSTAT6/STAT6 ratio. These data exclude the decrease of STAT6 protein expression by over-
night incubation with DHA and point to its exclusive direct interference in IL-4 signal transduc-
tion. These data are in line with previous reports by Gorjao et al. [102]. They detected a de-
creased IL-2 mediated JAK1 and JAK3 phosphorylation and consequently diminished STAT5 
phosphorylation through DHA. This was associated with a reduced surface expression of the 
IL-2 receptor resulting from an altered lipid raft organisation.  
Other studies confirmed that DHA has properties to interfere with lipid raft and membrane 
domains [62,68]. Stillwell et al. [103] recently described that dietary consumption of DHA cre-
ates DHA-rich membrane domains which lead to dislocation of sterol into sphingomyelin-rich 
lipid raft domains. In these environments the acyl chain order is extremely different. Thereby, 
protein movement between the domains is associated with a change of conformation and 
consequently has the potential to modulate cellular signalling. It has also been reported that 
DHA treatment causes stimulation of PLD1 activity in human PBMC by partial disorganisation 
of membrane microdomains, which results in activating the protein and disrupting signal 
transduction events [104]. Such mechanisms may apply for DHA action on STAT6 phos-
phorylation. This assumption is supported by the fact that DHA preincubation was necessary 
to reduce the IL-4 driven STAT6 phosphorylation possibly via downregulation of IL-4R ex-
pression. 
Even though, IL-4 plays a key role in the production of IgE by B cells [105] and provokes 
εGLT, IL-4 alone is not sufficient to induce IgE production. However, additionally to IL-4, 
CD40 signalling is indispensable for induction of the mature ε transcripts and consequent IgE 
synthesis [80,106,107].  
CD40 ligation, along with the other B cell stimuli, results in activation of transcription factors 
belonging to the Rel/NFκB family [13,14]. It is reported that genes involved in isotype swit-
ching like AID are regulated by type 1 but not type 2 NFκB activity [15]. Transcriptional regu-
lation by type 1 NFκB involves activation of IKK complex leading to degradation of IκBα and 
IκBβ and as a result release NFκB p50:p65 and p50:cRel dimers [108]. Additionally, mice 
lacking p50 show a clear reduction of IgE indicating the central role of p50 in IgE production 
[109]. Therefore, the impact of DHA on degradation of IκBα and nuclear translocation of p50 
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was investigated thoroughly. DHA reduced the anti-CD40 driven translocation of p50 into the 
nucleus, thereby affecting the second essential signal for IgE switch, IgE plasma cell devel-
opment and IgE production. These data are in line with previous reports showing that DHA 
inhibits NFκB activation [110,111]. Interestingly, DHA did not affect IκBα degradation which is 
an important upstream event for p50 release. However, NFκB can dissociate from phos-
phorylated IκBα and move into the nucleus without IκBα degradation, indicating that a re-
duced p50 translocation is not necessarily related to reduced IκB degradation [112].  
Another essential step for p50 translocation is its generation by processing from the precur-
sor p105. This sequence is initiated by ubiquitinylation, followed by gradual proteasomal deg-
radation of the p105 from the C-terminal end [15]. DHA acts probably via modulation of ubiq-
uitinylation [15] or alteration of proteasomal activity [113], consequently resulting in altered 
p50 translocation and thus modulated transcriptional activity.  
DHA inhibited the anti-CD40/IL-4 driven IgE production in PBMC of healthy individuals and 
allergic donors with lower serum IgE, but had no impact on PBMC of atopic patients with high 
serum IgE. Previous reports show that IgE hyperproduction in patients with atopic eczema is 
determined by constitutive and enhanced JAK3 phosphorylation in B cells [114]. This could 
explain the missing effect of DHA in patients with high serum IgE. The increased inherited 
JAK3 activation prevents the modulation of the IL-4 signalling pathway by DHA. 
DHA leads to a profound repression of the IgE switching process and thus IgE plasma cell 
development as well as IgE production in human B cells. This is caused by an early inhibition 
of CD40 and IL-4 signalling pathways resulting from a simultaneously decreased STAT6 and 
NFκB activation [115]. Therefore, the slight reduction of IgG secreting cells after treatment 
with 10 µM DHA may result from this concomitant inhibition, since CD40 ligation and IL-4 
induce not only IgE, but also IgG4 [107,116]. Hereby, DHA acted selectively on IgE isotype by 
means of immune modulation rather than suppression. These results comprise a strong bio-
logical relevance for the development of allergies, since it has been shown that the DHA con-
centrations used in this study correspond to serum levels found in humans [117]. More 
importantly, upon high dose DHA supplementation in patients with extrinsic atopic eczema 
the inhibition the anti-CD40/IL-4 driven IgE production in allergic PBMC can be also seen ex 
vivo [84].  
In terms of IgE production and its related signal transduction, these data reveal the early in-
terference of DHA in a possibly longer chain of events initiated by DHA. It cannot be ex-
cluded that DHA causes additional effects on IgE producing B cells later on. Thereby, modu-
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lation of eicosanoid synthesis, nuclear receptor binding and activation / repression, regulation 
of gene expression, alteration of cytokine production etc. may be potential effects provoked 
by DHA. Certainly, these observations might be important for dietary management of IgE 
mediated diseases and may offer an opportunity for a successful prevention of allergic dis-
eases.  
4.2 DHA supplementation in atopic eczema – a randomised, double 
blind, controlled study 
Several clinical trials have been conducted to ameliorate symptoms of atopic eczema by 
supplementation with n-6 PUFA. Based on the data generated so far, there is a lack of evi-
dence supporting the use of n-6 fatty acid supplementation on improvement the clinical out-
come of atopic eczema [30]. Due to its known antiinflammatory effects, some clinical trials 
have been also focused on fish oil supplementation [118,119]. Particularly, the beneficial effi-
ciency of DHA supplementation in vivo has been previously suggested by several studies 
[63].  
The assumption that DHA may be therapeutically effective in atopic eczema is based on the 
prerequisites that atopic eczema is an inflammatory disease which is amplified by an exces-
sive production of proinflammatory eicosanoids [120,121,122] and is associated with a ab-
normal fatty acid metabolism [28], that DHA supplementation acts antiinflammatorily (among 
others) by modulating eicosanoid generation [53] and there is a correlation between intake 
and a decreased risk of atopic eczema [123,124]. However, there were no accessible reports 
on clinical trial with dietary highly purified DHA in atopic eczema. Accordingly, a randomised, 
double blind, controlled trial was performed to evaluate the therapeutical impact of 8 week 
supplementation with 5.4 g of highly purified DHA daily in this atopic skin disorder. Thereby, 
DHA, but not the control treatment resulted in a significant clinical improvement of atopic ec-
zema in terms of a decreased SCORAD. A significant reduction of anti-CD40/IL-4 mediated 
IgE synthesis of PBMC was detected in DHA group only. Concomitantly, DHA treated patients 
showed an increase of plasma n-3 PUFA and a decrease of n-6/n-3 PUFA ratio. Finally, sup-
plementation led to a modulated activation status of PBMC in both groups [84]. However, 
there was no significant difference between DHA and control group. Thus, the possibility of a 
placebo effect cannot be excluded, despite the fact that DHA and control capsules were in-
distinguishable. Furthermore, the small study size limited the statistical power of these com-
parisons. Due to the lack of reported data showing the clinical efficacy of dietary DHA in 
atopic eczema the exact calculation of the necessary number of patients prior to this pilot 
study was not possible. Therefore, this exploratory trial with an arbitrary sample size was 
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performed. This limitation might have led to the possibility that randomisation was not likely to 
ensure the desired prognostic comparability between DHA and control group. However, both 
treated groups were well matched for gender, age and BMI and the study was double 
blinded. To determine whether the observed clinical effect of dietary DHA is of therapeutical 
significance needs further clarification and confirmation. 
As already demonstrated in former studies [125], an increased plasma n-3 PUFA proportion 
was detected in all patients consuming DHA [84]. Due to DHA treatment plasma fraction of 
DHA and EPA increased two- to threefold indicating an excellent compliance. The elevated 
EPA plasma level may be explained either by retroconversion of DHA to EPA when used in 
high doses [126] or the amount of EPA (0.4 g/d) contained in the used capsules or both. The 
detected clinical efficacy in therapy of atopic eczema points to antiinflammatory properties of 
DHA. Metabolism via COX and LOX pathways is highly dependent on the availability of lipid 
precursors [127,128]. Indeed, DHA does not directly act as a substrate for eicosanoid syn-
thesising enzymes, but inhibits AA metabolism [66] and serves as a precursor of n-3 eico-
sanoids via EPA [126]. DHA is known to reduce PGE2 production [66] and expression of PG 
synthesising enzyme COX-2 [68]. Accordingly, a favourable shift in eicosanoid formation may 
be responsible for several effects of DHA supplementation. In addition, DHA, possibly in 
combination with EPA, can act as precursor for COX and LOX driven bioactive lipids such as 
lipoxins, protectins and resolvins which are known to be antiinflammatory [129]. Importantly, 
an alteration of PUFA level following allergic sensitisation [130] as well as an involvement of 
n-6 PUFA derived mediators in the pathophysiology of atopic eczema is suggested since 
patients have an enhanced synthesis of these metabolites and thus increased concentrations 
of AA derived LT and PG in skin lesions [120,121]. Mayser et al. [32] demonstrated that daily 
infusions of n-3 PUFA effectively ameliorate the clinical outcome of atopic eczema. This 
therapeutical effect was accompanied by alterations in fatty acid profile of membrane lipid 
pool as well as changes in eicosanoid synthesis. Following the rise of free EPA an increase 
of n-3 PUFA derived metabolites was observed, which may also be associated with the clini-
cal improvement. Furthermore, it is speculated that a combination with dietary supplements 
is capable to enhance this therapeutical effect. However, patients of the DHA group showed 
a strong reduction of plasma n-6/n-3 PUFA ratio and a significant clinical improvement. It is 
likely that the fatty acid pattern in the skin was also altered in a similar way, since it has been 
shown that dietary n-3 PUFA supplementation is associated with their increased incorpora-
tion into skin [131]. EPA and DHA play an important role for stratum corneum and are there-
fore essential for maintaining a normal function and structure of skin barrier [132]. Addition-
ally, it is discussed that components of the lipid metabolism pathway are involved in 
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pathogenesis of atopic eczema and represent an opportunity to manage and perhaps even 
prevent subsequent atopic disorders through restorement of the barrier [133,134]. Willemsen 
et al. have recently shown that DHA effectively supports skin barrier integrity by improving 
resistance and permeability [135]. Lipid infusions may result in sufficient availability of fatty 
acids in skin. Whether this can also be achieved by oral supplementation needs to be inves-
tigated in further investigations.  
Extrinsic atopic eczema is associated with an unbalanced cytokine pattern promoting an IgE 
response to common environmental allergens [24]. In this study a reduced ex vivo 
anti-CD40/IL-4 mediated IgE synthesis by DHA supplementation was determined [84]. These 
data are in line with the B cell in vitro results showing the DHA mediated inhibition of 
anti-CD40/IL-4 driven IgE production comprising a strong biological relevance regarding the 
development of allergies.  
Since a change of total fat intake influences several immunological parameters [118] the con-
trol supplement contained the same amount of fat as the DHA capsules. Short to middle 
chained saturated fatty acids exhibit a low biological efficacy [136]. Hence, the control cap-
sules supplied the middle chained fatty acids, caprylic and capric acid. Therefore, the effects 
caused by an increased amount of dietary fat were intended to be eliminated.  
Analysis of the systemic IL-4 and IFNγ response revealed no impact by fatty acid supplemen-
tation suggesting that DHA acts rather locally than on systemic level. The determined non-
specific increased IL-4 with a concomitant decreased IFNγ may be attributed to seasonal 
influences resulting from natural exposure to allergens in spring [137]. However, the reduced 
IL-4 levels in control group suggest a potential immunological activity of the control supple-
ment. This is supported by the finding, that both, DHA and control supplementation led to 
significantly lower HLA-DR surface expression on monocytes and CD23 expression on B 
cells. This fact points to a requirement of a three-armed, placebo controlled study in order to 
compare DHA, an isoenergetic fatty acid control supplement and a placebo without any fat. 
Nevertheless, the unchanged anti-CD40/IL-4 stimulated IgE production within the control 
group suggests DHA specific pathways.  
In conclusion, although the sample size may be underpowered to detect small but relevant 
effects, the clinical results imply that dietary DHA may be beneficial for the standard treat-
ment of atopic eczema. It may not be excluded that different doses of DHA and long term 
treatment are more effective in atopic eczema. To deal with this subject, an extensive ran-
domised, placebo controlled, three-armed follow up trial should be performed.  
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4.3 Oral administration of DHA inhibits the development of eczema in a 
murine model of protein induced dermatitis  
A mouse model of allergen mediated dermatitis triggered by e.c. application of proteins was 
initially described by Wang et al. [44] and Spergel et al. [45]. To investigate the impact of oral 
DHA administration on pathogenesis of protein mediated dermatitis, this existing model was 
improved to achieve visible lesions. Thereby, the typical macroscopic skin characteristics as 
well as high response rates were evoked by initial systemic sensitisations implicating the 
importance of interactions between the local and systemic immune responses for clinical 
manifestation [85]. After all, OVA sensitised mice developed local inflammatory skin lesions 
which were clinically, histologically and immunologically comparable to human atopic ec-
zema. Lesional skin areas exhibited significant histological characteristics such as skin thick-
ening, increased cellular infiltrates containing CD4+, CD8+ T cells and MC as well as induced 
lesional expression of TH2 cytokines (IL-4, IL-10). These observations are consistent with 
reports on acute skin lesions in humans [26]. Additionally, elevated allergen specific IgE and 
IgG was detected in the serum of these mice [85].  
This small exploratory study was aimed to investigate the clinical efficacy of oral DHA ad-
ministration in a murine model of protein mediated dermatitis and to research into the under-
lying systemic and in particular local mechanisms of DHA effectiveness. Since there are only 
few data regarding supplementation of pure or highly enriched DHA in mice in general and no 
accessible data concerning protein induced eczema, this pilot study was performed with an 
arbitrary sample size. It is likely, that the small study size limited the statistical power and 
might have caused a failing of statistical significance comparing DHA and control group.  
In terms of skin disorders, merely Tomobe et al. [93] investigated the effects of 4.8 % DHA of 
total diet on the inflammatory response of contact hypersensitivity reactions. Since they used 
an extremely high dosage, the therapeutical range of DHA application had to be delineated in 
this study. Thereby, the applied DHA dose should have had an approximated dosage which 
is achievable by dietary intake in humans. Otherwise, humans and mice do not appear to be 
equally responsive to dietary n-3 PUFA, although a comparable pattern of changes in im-
mune cell PUFA content following supplementation was detected. It is known that the murine 
cell membranes contain initially more DHA and become more enriched with DHA relative to 
humans at comparable levels of DHA in the diet [128]. Consequently, a direct inference from 
humans to mice or vice versa is complicated. Nevertheless, this pilot study was performed to 
reveal the clinical efficacy of 2 % and 4 % DHA. 
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In this current investigation DHA supplementation led to an improved clinical outcome in a 
murine model of allergen induced dermatitis. The DHA mediated decrease of CSS was asso-
ciated with a reduced number of dermal CD8+ T cells. Thereby, supplementation with 2 % 
DHA in the diet was more potent to improve the clinical outcome of allergen induced dermati-
tis than 4 % DHA application.  
As discussed for human supplementation trial, DHA may mediate some of its favourable ef-
fects through changing the production of immunomodulatory lipid mediators and thus amelio-
rating the outcome of protein induced dermatitis [91,130,138].  
A mediator related effect of DHA may be associated with eicosanoid derived properties. This 
is supported by publications showing that amelioration of inflammatory and allergic symp-
toms by n-3 PUFA ingestion has been connected to reduction in 4-series and an increase in 
5-series of LT [139,140]. Interestingly, supplementation with 2 % DHA in the diet was more 
clinically efficient compared to 4 % DHA. Broughton et al. [141] have demonstrated that eico-
sanoid production in vivo is dependent on both, the n-3/n-6 ratio and the amount of total fat. 
High levels of dietary fat reduced 5-series LT synthesis simultaneously favouring synthesis of 
4-series LT in mice fed with diets containing high n-3/n-6 ratios. Thus, high fat intake may 
offset some benefits of n-3 PUFA supplementation. This immunological effect by increased 
total fat intake can be enhanced when DHA membrane content has reached the plateau 
[128]. Furthermore, it has to be considered that both DHA diets were prepared with different 
DHA blends containing additional fatty acids in varying concentrations. The mixtures might 
have influenced the outcome in both DHA supplementation groups respectively.  
DHA improved the clinical outcome of eczema but did not affect serum immunoglobulin con-
centration as determined in the human clinical study with DHA capsules as well [84]. Fur-
thermore, flow cytometric analysis of systemic cytokine response indicates no impact by oral 
DHA administration (data not shown). These data suggest that DHA operates rather on the 
local sites of inflammation than on the systemic immune response. Otherwise, the in vitro 
data show an inhibition of the IgE switching process. The question arises why DHA did not 
modulate the IgE response despite these in vitro findings. Probably, DHA supplementation 
was not capable to inhibit the in vivo IgE switching process since parallel DHA treatment and 
OVA sensitisation did not permit the sufficient DHA membrane loading [128]. Possibly, a pre-
ventive application of dietary DHA preceding the initial sensitisation may provoke this DHA 
mediated feature in vivo as well.  
T cells dominate the cellular infiltrate in eczematous skin lesions. Thereby, immigrating CD4+ 
and CD8+ T cells are shown be allergen specific [142,143,144]. DHA treatment did not alter 
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dermal infiltration of CD4+ T cells, but significantly reduced the number of dermal CD8+ cells. 
This finding was more prominent in mice fed with 2 % DHA compared to animals’ receiving 
4 % DHA. The role of epidermal CD8+ cells in pathogenesis of atopic eczema has been al-
ready suggested [142,145]. CD8+ T cells depleted mice fail to develop significant signs of 
inflammation upon allergen exposure, whereas CD4+ cell depletion does not prevent protein 
mediated eczema [146] suggesting CD8+ T cells as important effector cells in allergen in-
duced skin inflammation. Whether DHA causes this local reduction of CD8+ cells by in-
creased apoptosis [147,148] or decreased recruitment into skin will need further verification 
[149].  
Differential expression of ligands and their receptors allows tissue specific migration of T 
cells [148,150]. CLA is a marker for cells migrating into skin. CLA+ T cells are involved in 
pathogenesis of extrinsic atopic eczema and display a distinct expression profile of proteins 
involved in activation, differentiation, migration and apoptosis [148]. Skin homing CD8+ T 
cells are known to induce keratinocyte apoptosis, an important mechanism for induction and 
maintenance of eczema [151,152]. Importantly, responsiveness to oral n-3 PUFA administra-
tion for circulating immune cells is not the same as for tissue immune cells within the same 
lineage [128]. Thus, DHA may affect T cells in the skin in a different mode than blood T cells. 
Local production of chemotractant chemokines and the expression of their corresponding 
receptors on the cell surface are also involved in regulation of T cell migration [19]. CCL27 is 
a skin specific chemokine exclusively produced by epidermal keratinocytes and attracts 
CCR4 expressing TH2 cells into skin [153]. A modulation of the lesional chemokine produc-
tion by DHA thereby reducing the number of attracted CD8+ cells may be a possibility. 
Additionally, the interaction of keratinocytes with infiltrating T cells plays an essential role in 
pathology of atopic eczema [154]. Interestingly, keratinocytes become activated by interac-
tion with T cells through CD40/CD40L [154]. DHA inhibits CD40 dependent nuclear p50 
translocation in human B cells. Whether DHA operates in an analogous manner in mice has 
to be elucidated. However, own unpublished data reveal a prominent DHA mediated inhibi-
tion of IgE production in cultures of murine B cells upon anti-CD40/IL-4/LPS stimulation (data 
not shown). Potentially, CD40 signalling pathway in murine keratinocytes may be also tar-
geted and thus modulated by DHA. Keratinocytes release T cell attracting chemokines and 
influence T cells by their secreted cytokines hence contributing to disease progress [154]. 
Reduced keratinocyte activation might be partly responsible for DHA mediated amelioration 
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of allergen induced dermatitis. In vitro it has been already shown that DHA is capable to de-
crease production of TNFα and IL-8 in keratinocytes [155]. 
Nuclear hormone receptors, like RXR [156], LXR [157] and PPAR [149] are known to be in-
volved in skin homeostasis. Furthermore, their ligands modulate allergic immune response at 
the molecular level [158,159,160]. Therefore, agents stimulating these ligand activated tran-
scription factors are discussed as potential therapeutical target in combating atopic eczema 
[157]. 
Mice lacking RXRα/β in their epidermal keratinocytes display a chronic dermatitis mimicking 
that observed in atopic eczema patients. Furthermore, they exhibit a systemic syndrome 
similar to that found in these patients [161]. DHA has been demonstrated to bind to the RXR 
ligand binding domain [73,162], to recruit coactivator peptides [163] and to activate this tran-
scription factor [162,164]. Modulation of RXR activity can influence a broad spectrum of 
genes, since RXR acts as heterodimer with other nuclear receptors on transactivating tran-
scription [165]. 
PPAR have been identified in keratinocytes and play an important role in skin barrier function 
and regulation of skin inflammatory response [149,166]. PPARα deficient mice show in-
creased epidermal thickening, dermal recruitment of inflammatory cells in addition to in-
creased IgE and IgG2a production. In these mice inflammation was correlated to an unbal-
anced cytokine response and an increased expression of NFκB in the skin. PPAR ligands 
inhibit the secretion of chemokines thereby decreasing leukocyte recruitment to sites of in-
flammation [167]. Interestingly, PPARα expression was decreased in eczematous skin from 
atopic eczema patients, suggesting that defective PPARα expression might contribute to the 
pathology of this inflammatory skin disorder [168]. Consequently, PPAR activating molecules 
may regulate skin homoeostasis and may have therapeutical implications [149]. In this con-
text, DHA [164,169,170] and some of its derivates [171] are already shown to activate PPAR 
and so transcribing various PPAR dependent genes. 
Further on, LXR is also essential for epidermal permeability barrier homeostasis, since acti-
vation stimulates keratinocyte differentiation, lipid synthesis and increases lamellar bodies 
formation / secretion [166]. It is also reported that activators of LXRα and LXRβ exhibit potent 
antiinflammatory activity in models of allergic contact dermatitis [172]. Interestingly, there are 
evidences which suggest that DHA modulates LXR dependent gene expression [173,174]. 
Taken together, dietary DHA improves the clinical outcome of allergen induced dermatitis in 
mice by modulating the local immune response. DHA supplementation reduces the number 
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of dermal CD8+ T cells which are essentially involved in pathogenesis of murine dermatitis. 
The related mechanisms, like local prostanoid production, cytokine and chemokine expres-
sion as well as activation status of involved cell types have to be investigated. Additionally, 
further examinations are necessary for determination of optimal time point and dosage of 
DHA application for gaining maximum of information about the local processes in skin under 
DHA treatment. 
4.4 Conclusion 
Within the scope of a changing life style as well as altering dietary habits epidemiological and 
experimental data suggest a causal relation between the decreasing n-3 PUFA intake and 
the increasing prevalence of atopic diseases. Although complete prevention of atopic ec-
zema and other atopic disorders seems to be not feasible, interventions which modify dis-
ease expression may be possible. In order to improve allergy therapy the potential benefits of 
dietary DHA as well as its underlying mechanisms were investigated in vitro, in a mouse 
model of protein induced dermatitis and in a randomised clinical trial with atopic eczema pa-
tients. 
The in vitro investigation revealed that DHA acts directly on B cells leading to a profound re-
pression of the IgE switching process. Consequently, IgE plasma cell development and IgE 
production in human B cells is inhibited. This is caused by an early inhibition of CD40 and 
IL-4 signalling pathways resulting in a simultaneously decreased STAT6 and NFκB activation.  
Unanswered is still the question whether DHA is simply incorporated into phospholipids and 
exerts its effects through modulation of membrane properties or does DHA penetrates into 
cell and potentially binds to a specific receptor. Subcellular membrane fractionation of cells 
after incubation with radionucleotide labelled DHA may give information about the localisation 
of DHA in the cell. 
DHA inhibited the expression of εGLT in anti-CD40/IL-4 stimulated B cells. Does DHA also 
act on transcription of other germline transcripts like γGLT and αGLT? 
Furthermore, the data show that DHA application results in a reduced STAT6 phosphoryla-
tion. Whether this DHA mediated diminishment of IL-4 signalling is associated with a reduced 
JAK1 and JAK3 activation and / or an impairment of surface IL-4R complex expression has 
to be elucidated. 
DHA reduces the anti-CD40 driven nuclear NFκB p50 translocation without affecting IκBα 
degradation. The question arises whether DHA targets the liberation of p50 or does DHA 
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prevent the entry into nucleus. Are other members of the Rel/NFκB family affected as well? 
Analysis of IKK phosphorylation and investigation of cytosolic p105 may help to understand 
the basic mechanisms. 
Supplementation with 5.4 g/d highly purified DHA over 8 weeks resulted in a significant clini-
cal improvement of atopic eczema in this randomised, double blind, controlled trial. Addition-
ally, a significant reduction of anti-CD40/IL-4 mediated IgE synthesis of PBMC was detected 
in the DHA group only. These effects were associated with an increase of plasma n-3 PUFA 
and a decrease of n-6/n-3 PUFA ratio. However, supplementation did not affect the systemic 
cytokine production, but led to a modulated activation status of PBMC in both groups. 
Dietary DHA administration has directed to an impressive modulation of the plasma fatty acid 
spectrum. Whether this modification reflects the PUFA incorporation into the phospholipids of 
immune cells or particularly into membranes in skin lesions has to be elucidated. Further-
more, it has to be investigated whether the altered fatty acid profile leads to a favourable 
manipulation of eicosanoid production both locally and systemically. 
In the DHA group ex vivo anti-CD40/IL-4 mediated IgE synthesis was significantly inhibited. 
These findings illustrate the strong biological relevance of the in vitro data. Whether this inhi-
bition is caused by a diminished STAT6 and NFκB signalling in B cell can be discovered by 
analysis of B cells from DHA supplemented donors. 
The reduced activation status of PBMC in both groups implies a biological active control sup-
plement. Not only the quality, but also the quantity of lipids influences immunological parame-
ters. This fact points to a requirement of a three-armed, placebo controlled study in order to 
compare DHA, an isoenergetic fatty acid control supplement and a placebo without any fat. 
Thereby, the basic diet of participants might be defined and standardised to ensure compa-
rable premises. Additionally, study of local processes in lesional skin after DHA supplementa-
tion should be performed. This includes histological characterisation of cellular infiltrates 
(CD4+, CD8+, MC, DC), transcriptional analysis of local chemokines expression pattern (e.g. 
CCL27) and investigation of local PUFA phospholipid content as well as fatty acid mediator 
profile. 
In the last part of this thesis, the clinical efficiency of oral DHA administration was verified in a 
mouse model of allergen induced eczema thereby investigating local processes in eczema-
tous skin. DHA supplementation caused an improved clinical outcome of protein induced 
dermatitis. The DHA mediated amelioration was associated with a reduced number of dermal 
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CD8+ T cells. Interestingly, supplementation with 2 % DHA was more potent to improve the 
clinical outcome of allergen induced dermatitis than 4 % DHA application. However, DHA 
administration did not affect serum immunoglobulin concentrations. 
It is known that DHA administration alters the plasma fatty acid in mice [130]. In order to de-
lineate the local DHA mechanisms leading to an improved CSS, analysis of PUFA membrane 
content as well as local DHA metabolite generation has to be carried out.  
The clinical amelioration by oral DHA was associated with a reduced number of dermal 
CD8+. Further investigations to reveal the underlying trigger factors may imply the histological 
examinations of cell specific apoptosis and proliferation as well as keratinocyte activation. 
Since chemokines are involved in orchestrating cellular skin infiltration, expression analysis 
may be of importance. Moreover, DHA is a potential ligand of some nuclear receptors, which 
are described to be aphysiologically expressed in lesional skin of atopic eczema patients. 
Therefore, histological investigations of e.g. PPARα and NFκB in eczematous skin of DHA 
treated versus control fed mice might be of interest. 
Keratinocytes are involved in pathogenesis of atopic eczema and are known to be activated 
by T cell interaction through CD40/CD40L. This communication may be affected by DHA. In 
vitro investigations probably will reveal the direct impact of DHA on keratinocytes. Analysis of 
CD40 and NFκB expression may be thereby of importance.  
Finally, in order to achieve the full spectrum of DHA affects different DHA treatment protocols 
might be performed. Thereby, a preventive application of dietary DHA preceding the initial 
sensitisation may help to reach the sufficient DHA membrane loading for inhibition of IgE 
production in vivo. Potentially, DHA administration to the mothers before delivery or directly to 
offspring will be an opportunity. 
In summary these data show that dietary DHA has the capacity to influence the allergic im-
mune response. These current observations support previous reports suggesting the immu-
nomodulatory impact of this dietary component. Referring to this for achieving a selective 
manipulation of allergy it is necessary to promote the understanding of the underlying 
mechanisms of action of both DHA as well as its involved metabolites. 
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Appendix 
Antibodies  
Antibody Clone Manufacturer 
Anti-human CD4 PerCP  SK3 BD PharMingen, San Diego, USA 
Anti-human CD14 PE MφP9 BD PharMingen, San Diego, USA 
Anti-human CD19  Magnetic beads 
Miltenyi Biotec, Bergisch-Gladbach, 
Germany 
Anti-human CD19 FITC 4G7 BD PharMingen, San Diego, USA 
Anti-human CD20 FITC 2H7 eBioscience, San Diego, USA 
Anti-human CD23 APC EBVCS-5 BD PharMingen, San Diego, USA 
Anti-human CD27 FITC LG.7F9 eBioscience, San Diego, USA 
Anti-human CD27 PE LG.7F9 eBioscience, San Diego, USA 
Anti-human CD38 PE Cy5.5 HIT2 eBioscience, San Diego, USA 
Anti-human CD69 APC L78 BD PharMingen, San Diego, USA 
Anti-human CD138 APC MI15 BD PharMingen, San Diego, USA 
Anti-human CD40 82111 R&D, Minneapolis, USA 
Anti-human CD40 G28.5 DRFZ 
Anti-human CD28 L293, L25 BD PharMingen, San Diego, USA 
Anti-human HLA-DR PerCP L243 BD PharMingen, San Diego, USA 
Anti-human IFNγ FITC 4S·B3 BD PharMingen, San Diego, USA 
Anti-human IgA G20-359 BD PharMingen, San Diego, USA 
Anti-human IgG G18-145 BD PharMingen, San Diego, USA 
Anti-human IgE HP6061, HP6029  
Southern Biotech, Birmingham, 
USA 
Anti-human IgA, IgG, IgM Matched pairs 
Jackson ImmunoResearch, West 
Grove, USA 
Anti-human IκBα Alexa Fluor 
647 
L35A5 
Cell Signalling Technology Inc., 
Boston, USA 
Anti-human IL-4 PE  8D4-8 BD PharMingen, San Diego, USA 
Anti-human p50 H119  Santa Cruz, Heidelberg, Germany 
Anti-human pSTAT6 Alexa 
Fluor 647, (pY641) 
18 BD PharMingen, San Diego, USA 
Anti-human STAT6 PE 23 BD PharMingen, San Diego, USA 
Anti-mouse CD4 L3T4 BD PharMingen, San Diego, USA 
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Anti-mouse CD8 RM4-15 BD PharMingen, San Diego, USA 
Anti-mouse IgG1, biotin A85-1 BD PharMingen, San Diego, USA 
Anti-mouse IgG2a, biotin R19-15 BD PharMingen, San Diego, USA 
Anti-rabbit HRP Goat, Sc-2004 Santa Cruz, Heidelberg, Germany 
Anti-rat IgG, biotin Goat  BD PharMingen, San Diego, USA 
Purified mouse IgE, κ C38-2 BD PharMingen, San Diego, USA 
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Chemicals  
Chemicals / Reagents Manufacturer 
Acryl amide, 30 %  Roth, Karlsruhe, Germany 
Albumin from chicken egg white, Gade V  Sigma-Aldrich, Steinheim, Germany 
3-Amino-9-ethyl-carbazole (AEC) Sigma-Aldrich, Steinheim, Germany 
Ammunium persulfat (APS) Sigma-Aldrich, Steinheim, Germany 
Antibody diluent (Dako REALTM) DAKO Diagnostika, Hamburg, Germany 
Avidin/biotin blocking Kit  Vector, Burlingame, USA 
Beta mercapto ethanol Sigma-Aldrich, Steinheim, Germany 
Beriglobin® Novartis, Marburg, Germany 
Bovine serum albumine (BSA), pH 7.0 SERVA, Heidelberg, Germany 
Brefeldin A Sigma-Aldrich, Steinheim, Germany 
Calcium Ionophore, sterile Calbiochem-Merck, Darmstadt, Germany 
Carboxy-fluorescein diacetate, succinimidyl 
ester (CFSE) 
Molecular Probes Inc, Eugene, USA 
Citric acid, C6H8O7 Merck, Darmstadt, Germany 
Complete Protease Inhibitor Roche, Mannheim, Germany 
CpG oligodeoxynucleotides TIB MOLBIOL, Berlin, Germany 
CytofixTM Buffer BD PharMingen, San Diego, USA 
Detection System (Dako REAL, K 5005, Al-
kaline Phosphatase/RED) 
DAKO Diagnostika, Hamburg, Germany 
Developer, G153 AGFA, Cologne, Germany 
n,n-Dimethyl formamide (DMF) Sigma-Aldrich, Steinheim, Germany 
Disodium hydrogen phosphat, Na2HPO4 Merck, Darmstadt, Germany 
DNAse Macherey-Nagel, Düren, Germany 
Docosahexaenoic acid (DHA), C22H32O2 Cayman Chemicals, Ann Arbor, USA 
Docosahexaenoic acid (DHA), DHA500TG CRODA, Nettetal, Germany 
Docosahexaenoic acid (DHA), DHA700EE CRODA, Nettetal, Germany 
Diethanol amine, (HOCH2CH2)2NH Sigma-Aldrich, Steinheim, Germany 
ECL High performance Chemiluminescence 
film 
Amersham Buckinghamshire, United King-
dom 
ECL Plus Western Blot Detection Reagents 
Amersham, Buckinghamshire, United King-
dom 
Extra Avidine Peroxidase Sigma-Aldrich, Steinheim, Germany 
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FACS Flow BD PharMingen, San Diego, USA 
FastStart DNA Master SYBR® Green  Roche, Mannheim, Germany 
Fetal calf serum (FCS) Biochrom, Berlin, Germany 
Ficoll, sterile, d = 1,077 g/mL PAA, Pasching, Austria 
Goat serum (DakoCytomation, X0907) DAKO Diagnostika, Hamburg, Germany 
L-Glutamine Biochrom, Berlin, Germany 
Glycine SERVA, Heidelberg, Germany 
Hydrochloric acid, HCl , 25%  Merck, Darmstadt, Germany 
Hydrogen peroxide, H2O2, 30% Merck, Darmstadt, Germany 
Imject Alum Amersham Pierce, Rockford, USA 
Recombinant human Interleukin (IL)-4 Immunotools, Friesoythe, Germany 
Kaiser’s glycerol gelantine  Merck, Darmstadt, Germany 
Ketamine hydrochlorid (Ketamine) DeltaSelect, Dreiech, Germany 
Lysing Solution BD PharMingen, San Diego, USA 
Magnesium chloride, MgCl2 Merck, Darmstadt, Germany 
Methanol C2H5OH Merck, Darmstadt, Germany 
Milk powder (Blotting Grade) Roth, Karlsruhe, Germany 
NE-PER™ Nuclear and Cytoplasmic Extrac-
tion Reagents 
Pierce, Rockford, USA 
Para-Nitrophenyl phosphate Sigma-Aldrich, Steinheim, Germany 
Nucleospin II Kit Macherey-Nagel, Düren, Germany 
Papanicolaou’s solution (1a Harris’ haema-
toxylin solution)  
Merck, Darmstadt, Germany 
Paraformaldehyde (PFA) Sigma-Aldrich, Steinheim, Germany 
Pellet Paint™ Co-Precipitant Novagen, Madison, USA 
Penicillin, 10.000 E Biochrom, Berlin, Germany 
Permeabilizing Solution (PermII) BD PharMingen, San Diego, USA 
Dulbecco´s Phosphate-Buffered Saline 
(PBS), without Ca2+/Mg2+, sterile 
PAA, Pasching, Austria 
Phorbol-12-myristate-13-acetate (PMA), ste-
rile 
Sigma-Aldrich, Steinheim, Germany 
Phosphlow Perm Buffer BD PharMingen, San Diego, USA 
Physiological saline, 0.9 % NaCl Braun, Melsungen, Germany 
Potassium chloride, KCl  Merck, Darmstadt, Germany 
Potassium dihydrogen phosphat, KH2PO4 Merck, Darmstadt, Germany 
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Precision Plus Protein Standard Dual Bio-Rad, Munich, Germany 
Propidium iodide Sigma-Aldrich, Steinheim, Germany 
Proteinase K Macherey-Nagel, Düren, Germany 
ProTaqs Tris, pH 7.6 BIOCYC, Luckenwalde, Germany 
Rapid Fixer, G153 AGFA, Cologne, Germany 
Reverse Transcription Kit Applied Biosystems, Darmstadt, Germany 
RPMI 1640, without Ca2+/Mg2+, sterile Biochrom, Berlin, Germany 
Saponin Sigma-Aldrich, Steinheim, Germany 
Sodium carbonate, Na2CO3 Merck, Darmstadt, Germany 
Sodium chloride, NaCl Merck, Darmstadt, Germany 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, Steinheim, Germany 
Sodium hydrogen carbonate, NaHCO3  Merck, Darmstadt, Germany 
Staphylococcus Enterotoxine B (SEB) Sigma-Aldrich, Steinheim, Germany 
Streptavidin‐Horseradish Peroxidase 
(HRP), 100µg/mL  
R&D, Minneapolis, USA 
Streptavidin‐ Alkaline Phosphatase (AP)  ZYMED, San Francisco, USA 
Streptomycin (10.000 g/ml) Biochrom, Berlin, Germany 
Sulphuric acid, H2SO4, 95‐97% Riedel de Haen, Seelze, Germany 
Tetramethyl benzidine dihydrochloride, TMB Sigma-Aldrich, Steinheim, Germany 
Tetramethyl ethylene diamine (TEMED), 
C6H16N2 
Bio-Rad, Munich, Germany 
Toluidine blue O Merck, Darmstadt, Germany 
Tris(hydroxymethyl)aminomethane (Tris-
Base) 
Sigma-Aldrich, Steinheim, Germany 
Tween20 Bio-Rad, Munich, Germany 
Xylazine hydrochlorid (Rompun)  Bayer, Leverkusen, Germany 
Western Blot Loading Buffer DRFZ  
WST-1 reagent Boehringer Mannheim, Germany 
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Commodities and labware 
Commodities  Manufacturer 
6 Well plates, sterile  Suspension Greiner, Essen, Germany 
24 Well plates, sterile Tissue, suspension Greiner, Essen, Germany 
48 Well plates, sterile  Tissue, suspension Greiner, Essen, Germany 
96 Well plates, sterile Tissue, suspension Greiner, Essen, Germany 
96 Well plates (ELISA) Maxi sorb NUNC, Wiesbaden, Germany 
96 Well plates, sterile (ELIs-
pot) 
0.45 µm Hydrophob 
High Protein Binding 
Immibilion-P Memb-
rane 
Millipore, Schwallbach, Germany 
Biopsy punch, sterile 
4. 5 and 6 
mm diameter 
Stiefel , Offenbach, Germany 
Cohesive conforming ban-
dage 
Peha-haft, 6 cm width Hartmann, Heidenheim, Germany 
Cover slips   
Menzel-Gläser, Braunschweig, 
Germany 
Cryo spray Instant freezing spray Bio-optica, Milan, Italy 
Disposable hospital razor   Wilkinson, Solingen, Germany 
Disposable vinyl specimen  Cryomold Tissue-Tek Sakura, Torrance, USA 
Finn chambers  Epitest Ltd Oy, Tuusula, Finland 
Filter paper discs for Finn 
chambers 
7.5 mm diameter Epitest Ltd Oy, Tuusula, Finland 
Hamilton Pipette  Hamilton Company, Reno, USA 
Hypodermic needle, sterile 
0,45 x 25 mm, 26G 
x 1', Sterican 100 
Braun, Melsungen, Germany 
Light Cycler Capillaries  Roche, Mannheim, Germany 
Liquid Blocker Pap Pen Kisker-Biotech, Steinfurt, Germany 
Microscope slides  Super frost plus R. 
Langenbrinck, Emmendingen, Ger-
many 
O.C.T. medium  Tissue-Tek Sakura, Torrance, USA 
Ophthamic gel Vidisic Bausch & Lomb, Berlin, Germany 
Protean3 system  Bio-Rad, Munich, Germany 
Scalpel, sterile  No. 20  Feather, Osaka, Japan 
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Syringes, sterile 10ml, 20 ml, 50ml Braun, Melsungen, Germany 
Wattman Paper  
Schleicher & Schull, Dassel, Ger-
many 
Western Blot Cassette ECL Hypercassette 
Amersham Buckinghamshire, Uni-
ted Kingdom 
Western Blot Membrane 
Polyvinylidenfluorid 
(PVDF) 
Amersham Buckinghamshire, Uni-
ted Kingdom 
 
Reaction tubes, pipette tips and other commodities were used from Eppendorf, Falcon, and 
Sarstedt. 
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Equipment 
Equipment Model Manufacturer 
Autoclave   MELAG, Berlin, Germany 
Camera  EOS 20D Canon, Krefeldt, Germany 
Centrifuge  Megafuge 1.OR Heraeus, Hanau, Germany 
 Multifuge 4KR Heraeus, Hanau, Germany 
 5417R; 5417R Eppendorf, Hamburg, Germany 
 Minifuge RF Heraeus, Hanau, Germany 
Cryostat  Jung frigocut 2800N  Leica, Wetzlar, Germany 
Electronic cell counter  CASY 1, Modell TT Innovatis, Reutlingen, Germany 
ELISA reader  
Dynex MRX version 
1.33 
DYNATECH, Chantilly, USA 
ELISPOT reader 
CTL ImmunoSpot® 
S4 Analyzer 
C.T.L Cellular Technology, Cleve-
land, USA 
Flow bench HERA safe Heraeus, Hanau, Germany 
Flow cytometre  FACS Calibur 
Becton Dickinson, Heidelberg, Ger-
many 
Freezer (-20°C)/Fridge (4°C) TKF380  EUREKA, Emsdetten, Germany 
Freezer (-80°C) Hera Freeze Heraeus, Hanau, Germany 
Gel chamber 40 1214 peqLab  
PEQLAB Biotechnologie, Erlangen, 
Germany 
Gradient cycler Px2 Thermal Cycler Thermo, Hamburg, Germany 
Hot plate  nuova II Thermolyne, Dubuque, USA 
Incubator HERA cell Heraeus, Hanau, Germany 
Lab balance  Sartorius, Göttingen, Germany 
Light Cycler  LightCycler 1.5 Roche, Mannheim, Germany 
Magnetic cell sorter autoMACS Separator 
Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Magnetic stirrer Magnetmix 2070 
Hecht-Assistent, Sondenheim, Ger-
many 
Microscope  
Axioskop and Axi-
oplan2 imaging 
Carl Zeiss, Jena, Germany 
Microscope camera  Axio Cam HRc Carl Zeiss, Jena, Germany 
Pipets 10µl, 100µl, 200µl; Eppendorf, Hamburg, Germany 
Appendix 
 
 
104
1000µl; multichannel, 
multistepper 
Pipettors Pipetus 
Hirschmann Laborgeräte, Eberstadt, 
Germany 
pH electrode  NEOLAB, Heidelberg, Germany 
pH-metre  MV 870 Digital PRÄCITRONIC, Dresden, Germany 
Power Supply PowerPac300 Bio-Rad, Munich, Germany 
Rotator Coulter Mixer 
Denleytech, Woking, United King-
dom 
Shaker IKA-VIBRAX-VXR IKA, Staufen, Germany 
Spectrophotometre  ND-1000  NanoDrop, Wilmington, USA 
Ultrasonic bath Sonorex TK52 Bandelin, Berlin, Germany 
Vortex  REAX 2000 Heidolph, Schwabach, Germany 
Water bath  GFL1092 JULABO, Seelbach, Germany 
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Software  
Software Manufacturer 
Axio Vision LE Application 4.5.0.0  Carl Zeiss, Jena, Germany 
ImmunoSpot v4.0.13 C.T.L Cellular Technology, Cleveland, USA 
Light Cycler Software Version 3 Roche, Mannheim, Germany 
NCBI databases 
National Center for Biotechnology Informa-
tion Bethesda, USA 
ND-1000 NanoDrop, Wilmington, USA 
Primer 3 SourceForge, Mountain View, USA 
Revelation G3.2 DYNEX, Berlin, Germany 
SPSS (Statistical Package for the Social 
Sciences) for Windows, Release 12.0 & 14.0 
 SPSS Inc., Chicago, USA 
UCSC databases 
UCSC Genome Bioinformatics Group, Santa 
Cruz, USA 
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Buffers and solutions  
ACE-DMF buffer (pH 5.0) 64 mM Sodium acetate 
 45 mM Acetate 
  
Blotting buffer 25 mM Tris-base 
 190 mM glycine 
 20 % v/v Methanol 
  
Diethanol amine buffer (pH 9.9) 840 mM Diethanol amine 
 1.1 mM MgCl2 
  
FACS buffer  PBS 
 1 % BSA 
  
MACS buffer PBS 
 20 mM EDTA 
 0.2 % BSA 
  
Medium complete 
500 mL RPMI1640, with 2.0 g/L NaHCO3, 
with stabile glutamine 
 50 mL FCS 
 100 U/mL Penecillin 
 100 µg/mL Streptomycin 
  
Ketamine / Rompun (8 : 1 : 1) 0.9 % NaCl : 
 50 mg/mL Ketamine 
 2 % Rompun 
  
Running buffer  25 mM Tris-base 
 190 mM Glycine 
 7 mM SDS 
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Separating gel (5 %) 5 % v/v Acryl amide 
 0.125 M Tris Buffer 
 0.1 % v/v SDS 
 0.1 % v/v APS 
 0.01 % v/v TEMED 
  
Sodium carbonate buffer (pH=9.0)  45 mM NaHCO3 
 9.1 M Na2CO3 
  
Stacking gel 12 % v/v Acryl amide 
 0.5 M Tris Buffer 
 0.1 % v/v SDS 
 0.1 % v/v APS 
 0.04 % v/v TEMED 
  
TMB buffer (pH=5.5)  51.4 mM Na2HPO4 
 24.3 mM citric acid 
  
Tris-buffered saline (TBS) 20 mM Tris-Base 
 75 mM NaCl 
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List of abbreviations 
AA Arachidonic acid, 20:4n-6 
AICD Activation induced cell death 
AID Activation induced (cytidine) desaminase  
ALA α-linolenic acid, 18:3n-3 
AP-1 Activator protein 1  
APC Antigen presenting cell 
BMI Body mass index 
CH Heavy chain constant regions 
CLA Cutaneous lymphocyte-associated antigen 
COX Cyclooxygenase 
CSS Clinical skin score  
CSR Class switch recombination 
DAG Diacylglycerol  
DC Dendritic cells 
DGLA Dihomo-gamma linolenic acid, 20:3n-6 
DHA Docosahexaenoic acid, 22:6n-3 
e.c. Epicutaneous  
εGLT Epsilon germline transcript 
ELISA Enzyme Linked Immuno Assay 
ELIspot Enzyme Linked Immuno Spot Technique 
EPA Eicosapentaenoic acid, 20:5n-3 
ERK Extracellular signal-regulated kinase 
FACS Fluorescence activated cell sorter 
FcεRI High affinity receptor for IgE 
FLG Filament-aggregating protein 
FSC Forward light scatter  
g Acceleration of gravity 
GCK Germinal center kinase 
GLA γ-linoleic acid, 20:3n-6 
HDL High density lipoprotein 
HLA human leukocyte antigen 
HPRT Hypoxanthine-Guanine Phosphoribosyltransferase 
Ig Immunoglobulin 
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IDEC Inflammatory dendritic epidermal cells 
IFN Interferon 
IκB inhibitor of NFκB 
IKK inhibitor of NFκB (IκB) kinase  
IL- Interleukin 
IL-4R Interleukin-4 Receptor 
i.p. Intraperitoneal 
IRS- Insulin receptor substrate 
ITIM Immuno-tyrosine inhibitory motif  
JAK Janus activated kinase 
JNK c-jun kinase 
LA Linoleic acid, 18:2n-6 
LC Langerhans cells 
LOX Lipoxygenase 
LT Leukotriene 
LXR Liver X receptor 
MACS Magnetic cell sorting  
MAPK Mitogen-activated protein kinase  
MEKK1 MAPK/ ERK kinase kinase 1 
MFI Mean fluorescence intensity 
MHC II Major histocompatibility complex II  
min Minute 
MO Monocyte 
n.d. Not detectable 
NFκB Nuclear factor kappa B 
NIK NFκB inducing kinase 
n.s. Not significant 
OA Oleic acid, 18:1n-9 
OVA Ovalbumin 
PBMC Peripheral blood mononuclear cells 
PG Prostaglandin  
PI3-K Phosphatidylinositol 3-kinase 
PKC Protein kinase C 
PL Phospholipase 
PPAR Peroxisome proliferator-activated receptor 
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pSTAT6 Phosphorylated signal transducer and activator of transcription 6 
PUFA Polyunsaturated fatty acids 
RT-PCR Reverse-transcriptase polymerase chain reaction 
RXR Retinoic acid X receptor 
S. aureus Staphylococcus aureus  
SCORAD Severity Scoring of Atopic Dermatitis 
SH2 Src homology domain 2 
Shp-1 SH2-containing tyrosine phosphatase--1 
SREBP Sterol regulatory-element binding protein 
SSC Side light scatter 
STAT6 Signal transducer and activator of transcription 6  
TH1/2 T Helper cell type 1/2 
TNF Tumor necrosis factor  
TRAF TNF-receptor-associated factor 
Treg Regulatory T cells 
TSLP Thymic stromal lymphopoietin 
TX Thromboxane 
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